<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Mol. Cancer</journal-id><journal-title-group><journal-title>Molecular Cancer</journal-title></journal-title-group><issn pub-type="epub">1476-4598</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5112703</article-id><article-id pub-id-type="pmid">27852308</article-id><article-id pub-id-type="publisher-id">554</article-id><article-id pub-id-type="doi">10.1186/s12943-016-0554-y</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Systems analysis identifies miR-29b regulation of invasiveness in melanoma</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Andrews</surname><given-names>Miles C.</given-names></name><address><email>miles.andrews@onjcri.org.au</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Cursons</surname><given-names>Joseph</given-names></name><address><email>joseph.cursons@unimelb.edu.au</email></address><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff6">6</xref><xref ref-type="aff" rid="Aff7">7</xref><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Hurley</surname><given-names>Daniel G.</given-names></name><address><email>daniel.hurley@unimelb.edu.au</email></address><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff7">7</xref><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Anaka</surname><given-names>Matthew</given-names></name><address><email>matt.anaka@gmail.com</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Cebon</surname><given-names>Jonathan S.</given-names></name><address><email>jonathan.cebon@onjcri.org.au</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Behren</surname><given-names>Andreas</given-names></name><address><email>andreas.behren@onjcri.org.au</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Crampin</surname><given-names>Edmund J.</given-names></name><address><email>edmund.crampin@unimelb.edu.au</email></address><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff6">6</xref><xref ref-type="aff" rid="Aff7">7</xref><xref ref-type="aff" rid="Aff8">8</xref></contrib><aff id="Aff1"><label>1</label>Olivia Newton-John Cancer Research Institute, Heidelberg, VIC 3084 Australia </aff><aff id="Aff2"><label>2</label>Ludwig Institute for Cancer Research, Melbourne-Austin Branch, Cancer Immunobiology Laboratory, Heidelberg, VIC 3084 Australia </aff><aff id="Aff3"><label>3</label>School of Cancer Medicine, La Trobe University, Heidelberg, VIC 3084 Australia </aff><aff id="Aff4"><label>4</label>Department of Medicine, University of Melbourne, Parkville, VIC 3010 Australia </aff><aff id="Aff5"><label>5</label>Systems Biology Laboratory, University of Melbourne, Parkville, VIC 3010 Australia </aff><aff id="Aff6"><label>6</label>ARC Centre of Excellence in Convergent Bio-Nano Science, University of Melbourne, Parkville, VIC 3010 Australia </aff><aff id="Aff7"><label>7</label>School of Mathematics and Statistics, University of Melbourne, Parkville, VIC 3010 Australia </aff><aff id="Aff8"><label>8</label>Centre for Systems Genomics, University of Melbourne, Parkville, VIC 3010 Australia </aff><aff id="Aff9"><label>9</label>Department of Medicine, University of Toronto, Toronto, ON Canada </aff></contrib-group><pub-date pub-type="epub"><day>16</day><month>11</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>16</day><month>11</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>15</volume><elocation-id>72</elocation-id><history><date date-type="received"><day>2</day><month>6</month><year>2016</year></date><date date-type="accepted"><day>31</day><month>10</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2016</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>In many cancers, microRNAs (miRs) contribute to metastatic progression by modulating phenotypic reprogramming processes such as epithelial-mesenchymal plasticity. This can be driven by miRs targeting multiple mRNA transcripts, inducing regulated changes across large sets of genes. The miR-target databases TargetScan and DIANA-microT predict putative relationships by examining sequence complementarity between miRs and mRNAs. However, it remains a challenge to identify which miR-mRNA interactions are active at endogenous expression levels, and of biological consequence.</p></sec><sec><title>Methods</title><p>We developed a workflow to integrate TargetScan and DIANA-microT predictions into the analysis of data-driven associations calculated from transcript abundance (RNASeq) data, specifically the mutual information and Pearson&#x02019;s correlation metrics. We use this workflow to identify putative relationships of miR-mediated mRNA repression with strong support from both lines of evidence. Applying this approach systematically to a large, published collection of unique melanoma cell lines &#x02013; the Ludwig Melbourne melanoma (LM-MEL) cell line panel &#x02013; we identified putative miR-mRNA interactions that may contribute to invasiveness. This guided the selection of interactions of interest for further in vitro validation studies.</p></sec><sec><title>Results</title><p>Several miR-mRNA regulatory relationships supported by TargetScan and DIANA-microT demonstrated differential activity across cell lines of varying matrigel invasiveness. Strong negative statistical associations for these putative regulatory relationships were consistent with target mRNA inhibition by the miR, and suggest that differential activity of such miR-mRNA relationships contribute to differences in melanoma invasiveness. Many of these relationships were reflected across the skin cutaneous melanoma TCGA dataset, indicating that these observations also show graded activity across clinical samples. Several of these miRs are implicated in cancer progression (miR-211, -340, -125b, &#x02212;221, and -29b). The specific role for miR-29b-3p in melanoma has not been well studied. We experimentally validated the predicted miR-29b-3p regulation of LAMC1 and PPIC and LASP1, and show that dysregulation of miR-29b-3p or these mRNA targets can influence cellular invasiveness in vitro.</p></sec><sec><title>Conclusions</title><p>This analytic strategy provides a comprehensive, systems-level approach to identify miR-mRNA regulation in high-throughput cancer data, identifies novel putative interactions with functional phenotypic relevance, and can be used to direct experimental resources for subsequent experimental validation.</p><p>Computational scripts are available: <ext-link ext-link-type="uri" xlink:href="http://github.com/uomsystemsbiology/LMMEL-miR-miner">http://github.com/uomsystemsbiology/LMMEL-miR-miner</ext-link>
</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1186/s12943-016-0554-y) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Systems biology</kwd><kwd>Cancer</kwd><kwd>micro-RNA</kwd><kwd>Melanoma</kwd><kwd>Phenotypic switching</kwd><kwd>Statistical association</kwd><kwd>TargetScan</kwd><kwd>DIANA-microT CDS</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000925</institution-id><institution>National Health and Medical Research Council</institution></institution-wrap></funding-source><award-id>1055456</award-id><principal-award-recipient><name><surname>Andrews</surname><given-names>Miles C.</given-names></name></principal-award-recipient></award-group><award-group><funding-source><institution>Ludwig Cancer Research</institution></funding-source></award-group><award-group><funding-source><institution>Victorian State Government Operational Infrastructure Support Program</institution></funding-source></award-group><award-group><funding-source><institution>Centre of Excellence in Convergent Bio-Nano Science and Technology, Australian Research Council</institution></funding-source><award-id>CE140100036</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>Phenotypic switching is an important process that facilitates melanoma progression, metastasis, and resistance to therapy [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR6">6</xref>]. Despite the neural crest (i.e. non-epithelial) origin of melanocytes, melanomas display cadherin-switching and functional behaviours that resemble epithelial-to-mesenchymal plasticity (EMP). Melanomas often harness lineage-specific molecular pathways from more primitive (less-differentiated) states in order to switch between proliferative, minimally-invasive (i.e. &#x02018;epithelial-like&#x02019;, or &#x02018;E-like&#x02019;) and invasive, minimally-proliferative (i.e. &#x02018;mesenchymal-like&#x02019;, or &#x02018;M-like&#x02019;) phenotypes [<xref ref-type="bibr" rid="CR7">7</xref>&#x02013;<xref ref-type="bibr" rid="CR9">9</xref>]. Several transcription factors, including ZEB1/2, SNAIL1/2, TWIST1/2, MITF and JUN, have been shown to play key roles in melanoma EMP-like processes [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]; however, the mechanisms by which internal and micro-environmental signals are integrated to modulate transcriptional activity are not fully understood.</p><p>Micro-RNAs (miRs) are short (18&#x02013;24 nucleotide) non-coding RNAs which play an important role regulating the activity of other RNA transcripts. They have been implicated in the oncogenesis and progression of several cancers, as reviewed thoroughly elsewhere [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. Some miRs directly target important transcription factors, such as miR-200 regulation of ZEB in epithelial carcinomas [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>], while in melanoma, miR-148 mediated dysregulation of MITF [<xref ref-type="bibr" rid="CR15">15</xref>] and miR-125b control of JUN [<xref ref-type="bibr" rid="CR16">16</xref>] have been noted. In melanoma, a network of miRs, including miR-211 and miR-222 has been shown to mediate some effects of oncogenic BRAF signalling [<xref ref-type="bibr" rid="CR17">17</xref>]. ArrayCGH studies suggest miR-29b copy number increases in melanoma and a number of miRs have been implicated in melanocyte transformation [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>], melanoma progression [<xref ref-type="bibr" rid="CR20">20</xref>&#x02013;<xref ref-type="bibr" rid="CR23">23</xref>], modulating the extent and mode of melanoma cell invasiveness [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>], and switching of cellular phenotype (i.e. epithelial-mesenchymal plasticity) in a number of epithelial cancers [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>].</p><p>Identifying endogenous miRs that play a key role in oncogenesis remains challenging for a number of reasons. Firstly, within mammalian cells, miRs exert their effects through multiple mechanisms that are difficult to observe experimentally utilising any single current method. Multiple lines of evidence have shown that miRs regulate protein abundance by modulating protein translation [<xref ref-type="bibr" rid="CR28">28</xref>], influencing mRNA transcript stability [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>] or through both effects [<xref ref-type="bibr" rid="CR31">31</xref>]. These effects may not be entirely independent [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>], and it has been argued that changes in mRNA stability can be attributed to repression of translation [<xref ref-type="bibr" rid="CR33">33</xref>]. A recent review has detailed the molecular mechanisms mediating target transcript sequestration or degradation, and translational inhibition [<xref ref-type="bibr" rid="CR32">32</xref>].</p><p>Secondly, there is extensive &#x02018;crosstalk&#x02019; and broader, coordinated targeting by miRs [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR34">34</xref>], by virtue of the mapping of miRs to multiple potential transcript targets with potentially different binding affinities. One common effect which influences miR activity is variation in the abundance of alternative RNA targets within the intracellular milieu &#x02013; although the effect of protein-coding competitive endogenous RNAs (ceRNAs) is thought to be minimal [<xref ref-type="bibr" rid="CR35">35</xref>], non-coding ceRNAs [<xref ref-type="bibr" rid="CR36">36</xref>] and circular RNAs [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>] have been shown to act as miRNA &#x0201c;sinks&#x0201d; which exert biological effects in a combinatorial fashion. Together, these effects make it difficult to identify individual miR-mRNA interactions which are consistent across many experimental systems and conditions.</p><p>Finally, well-known differences between cellular processes active in transformed cell lines and in primary tissues taken from patients lead to a differing repertoire of miRs, transcripts, and metabolic intermediates. As a direct consequence, experimental results observed in one model system, particularly in cell lines, may not be observable in or relevant to patient tumours in vivo [<xref ref-type="bibr" rid="CR39">39</xref>]. Overcoming these challenges requires an integrative systems analysis relating miR abundance to target mRNA abundance, as well as to a relevant phenotype. Here we report such an analysis using the Ludwig Melbourne melanoma (LM-MEL) cell line panel [<xref ref-type="bibr" rid="CR40">40</xref>], an experimental resource designed for the identification and verification of molecular mechanisms contributing to the heterogeneity observed across melanoma tumours.</p><p>The LM-MEL panel data were collected from 57 established melanoma cell lines [<xref ref-type="bibr" rid="CR40">40</xref>] which display a range of phenotypes across the epithelial-like to mesenchymal-like spectrum [<xref ref-type="bibr" rid="CR41">41</xref>]. The original LM-MEL molecular data were supplemented with miR transcript abundance data (Additional file <xref rid="MOESM1" ref-type="media">1</xref>), and information on invasiveness through matrigel (Additional file <xref rid="MOESM2" ref-type="media">2</xref>), which allowed us to identify putative interactions between miRs and mRNAs associated with differences in the functional phenotypes of these melanoma cell lines.</p><p>We applied statistical measures of association (Pearson&#x02019;s correlation [r<sub>P</sub>] and mutual information [MI]) together [<xref ref-type="bibr" rid="CR42">42</xref>] to identify miRs and mRNAs which showed a strong inverse association across the LM-MEL dataset. Mutual information is an information-theoretic metric that measures divergence from statistical independence [<xref ref-type="bibr" rid="CR43">43</xref>]. It contains a <inline-formula id="IEq1"><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ \log \left(\frac{P\left(A,B\right)}{P(A)P(B)}\right) $$\end{document}</tex-math><mml:math id="M2"><mml:mo>log</mml:mo><mml:mfenced close=")" open="("><mml:mfrac><mml:mrow><mml:mi>P</mml:mi><mml:mfenced close=")" open="(" separators=","><mml:mi>A</mml:mi><mml:mi>B</mml:mi></mml:mfenced></mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mfenced close=")" open="("><mml:mi>A</mml:mi></mml:mfenced><mml:mi>P</mml:mi><mml:mfenced close=")" open="("><mml:mi>B</mml:mi></mml:mfenced></mml:mrow></mml:mfrac></mml:mfenced></mml:math><inline-graphic xlink:href="12943_2016_554_Article_IEq1.gif"/></alternatives></inline-formula> term that tends to zero with statistical independence, where <italic>P</italic>(<italic>A</italic>,&#x02009;<italic>B</italic>)&#x02009;=&#x02009;<italic>P</italic>(<italic>A</italic>)<italic>P</italic>(<italic>B</italic>). Mutual information and MI-based metrics have been successfully applied for the analysis of large biological data sets [<xref ref-type="bibr" rid="CR44">44</xref>&#x02013;<xref ref-type="bibr" rid="CR46">46</xref>] (<italic>further details within</italic>
<xref rid="Sec13" ref-type="sec">Methods</xref>/<xref rid="Sec21" ref-type="sec">Statistical associations</xref>). Conversely, Pearson&#x02019;s correlation purely measures the tendency towards a linear association, although it does provide directionality through positive/negative values.</p><p>This report describes a systems approach to identify putative regulatory miR-mRNA relationships across related cell lines and clinical samples, applying measures of statistical association and refining the results through the principled inclusion of knowledge from specific relevant databases. Our computational workflow identifies a novel role for miR-29b-3p in regulating melanoma invasiveness, and the results improve our understanding of how miR activity can influence melanoma phenotype switching and EMP.</p></sec><sec id="Sec2"><title>Results</title><sec id="Sec3"><title>Changes in miR abundance were predicted to regulate mRNA transcript stability across a panel of melanoma cell lines</title><p>Given the evidence implicating miRs in cancer progression and invasiveness, we hypothesised that miRs with differential activity across the LM-MEL cell line panel may drive post-transcriptional regulatory changes that influence cell phenotype. To identify relationships where miRs may regulate mRNA transcripts through reduced stability, we examined miR and mRNA transcript abundance across the LM-MEL cell line panel and selected those with a strong, negative (or inverse) statistical association between miR and mRNA abundance (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1a</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p>Systems analysis of database-enriched statistical associations between miR and mRNA transcripts. <bold>a</bold> Density and contour plot for mutual information and Pearson&#x02019;s correlation between transcript abundance of all miR and mRNA pairs across the LM-MEL cell line panel (<italic>n</italic>&#x02009;=&#x02009;57). Associations within the top 10% of mutual information values (<italic>vertical dashed line</italic>) and bottom (most negative) 2.5% of Pearson&#x02019;s correlation values (<italic>horizontal dashed lines</italic>) were selected as those with strong negative associations (<italic>relative fraction of associations in red</italic>). <bold>b</bold> These associations (<bold>a</bold>, <italic>bottom right</italic>) were matched against high-confidence, predicted relationships from TargetScan and DIANA-microT, and previously validated relationships from miRTarBase. Relationships between hsa-miR-29b-3p and LAMC1, LASP1, and PPIC are examined below, Additional file <xref rid="MOESM3" ref-type="media">3</xref> lists all putative relationships</p></caption><graphic xlink:href="12943_2016_554_Fig1_HTML" id="MO1"/></fig>
</p></sec><sec id="Sec4"><title>Numerous known and predicted miR-mRNA interactions show evidence of post-transcriptional regulation across the LM-MEL cell line panel</title><p>We integrated TargetScan [<xref ref-type="bibr" rid="CR47">47</xref>&#x02013;<xref ref-type="bibr" rid="CR49">49</xref>] and DIANA-microT [<xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR51">51</xref>] (Additional file <xref rid="MOESM1" ref-type="media">1</xref>) to limit the search space for putative miR-mRNA interactions. Numerous strong, negative associations across the LM-MEL data were supported by sequence-based predictions with a relatively high confidence (TargetScan top 15<sup>th</sup> percentile; and/or DIANA-microT top 30<sup>th</sup> percentile; details in <xref rid="Sec13" ref-type="sec">Methods</xref>/<xref rid="Sec22" ref-type="sec">Databases</xref>). Matching putative relationships to miRTarBase (using &#x02018;strong evidence&#x02019; experimental methods), only a small sub-set of interactions appear to have been previously validated (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1b</xref>). A full list of predicted relationships is given in Additional file <xref rid="MOESM3" ref-type="media">3</xref> with further details.</p></sec><sec id="Sec5"><title>Putative regulatory associations contain a number of previously validated associations</title><p>Selected relationships are shown in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref> using in vitro LM-MEL data with phenotypic annotations (top of panel; red, high matrigel-invasiveness cell lines; blue, low invasiveness), and in vivo TCGA [<xref ref-type="bibr" rid="CR52">52</xref>] Skin Cutaneous Melanoma (SKCM) data (bottom of panel).<fig id="Fig2"><label>Fig. 2</label><caption><p>Many putative miR-mRNA relationships involve mRNAs previously implicated in EMP and melanoma phenotype switching. LM-MEL and TCGA (<italic>top and bottom subplots, respectively</italic>) transcript abundance data for (<bold>a</bold>-<bold>h</bold>) selected, previously validated relationships (miRTarBase, &#x02018;strong experimental evidence&#x02019;; <italic>see</italic>
<xref rid="Sec13" ref-type="sec">Methods</xref>/<xref rid="Sec22" ref-type="sec">Databases</xref>), and (<bold>i</bold>-<bold>q</bold>) putative relationships regulating mRNAs implicated in melanoma phenotype switching by Widmer et al. [<xref ref-type="bibr" rid="CR3">3</xref>]. Further details are given in Additional file <xref rid="MOESM4" ref-type="media">4. Predicted regulatory interactions involving SOX transcription factors integral to melanoma phenotype switching are shown (<bold>r-s</bold>).</xref>
</p></caption><graphic xlink:href="12943_2016_554_Fig2_HTML" id="MO2"/></fig>
</p><p>Several putative relationships have been validated across different human cell systems (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2a</xref>-<xref rid="Fig2" ref-type="fig">h</xref>; &#x02018;miRTarBase validated&#x02019;), and were supported by TCGA data (<italic>further details within</italic> Additional file <xref rid="MOESM4" ref-type="media">4</xref>). In parallel, a number of putative relationships emerged which have not been previously observed within human cell lines, and many of these potentially novel relationships involved mRNA transcripts implicated in melanoma phenotype switching [<xref ref-type="bibr" rid="CR3">3</xref>] and invasive behaviours (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2i</xref>-<xref rid="Fig2" ref-type="fig">q</xref>; Additional file <xref rid="MOESM4" ref-type="media">4</xref>).</p><p>Within the unvalidated interactions, the predicted regulatory interactions between the transcription factors SOX9 and miR-502-3p (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2r</xref>; LM-MEL r<sub>P</sub>&#x02009;=&#x02009;&#x02212;0.50, MI&#x02009;=&#x02009;0.33; TCGA r<sub>P</sub>&#x02009;=&#x02009;&#x02212;0.13), and SOX10 and miR-222-3p (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2s</xref>; LM-MEL r<sub>P</sub>&#x02009;=&#x02009;&#x02212;0.61, MI&#x02009;=&#x02009;0.37; TCGA r<sub>P</sub>&#x02009;=&#x02009;&#x02212;0.19), is particularly interesting. In melanoma, SOX10 functions both independently and in cooperation with MITF to promote more differentiated and/or proliferative cellular states [<xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR54">54</xref>]. A SOX10-low state is associated with reduced cell proliferation and engagement of EMT-like processes in melanoma to promote more invasive phenotypes [<xref ref-type="bibr" rid="CR55">55</xref>] - a state maintained, in part, through mutual-antagonism with the closely related transcription factor SOX9 [<xref ref-type="bibr" rid="CR56">56</xref>]. SOX10 suppression contributes to BRAF- and/or MEK-inhibitor resistance in BRAF mutated melanoma, by activating TGF&#x003b2; signalling to upregulate EGFR and PDGFRB [<xref ref-type="bibr" rid="CR57">57</xref>], whilst increasing SOX9 transcript abundance has been observed in breast cancer EMT [<xref ref-type="bibr" rid="CR58">58</xref>]. SOX9-high LM-MEL cell lines are also enriched for an invasive phenotype (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2r</xref>) and there is a distinct subset of SOX10-low, high-invasive LM-MEL cell lines (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2s</xref>) which appears to be recapitulated within the TCGA data.</p></sec><sec id="Sec6"><title>A number of miRs implicated in the progression of melanoma and other cancers were enriched for relationships with differential regulatory activity</title><p>As detailed earlier, miRs can drive phenotypic change through the coordinated regulation of several mRNA targets. To examine this we calculated the relative enrichment of &#x02018;active associations&#x02019; (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1b</xref>) for each miR across the LM-MEL data. The top five miRs when using high confidence TargetScan lists were miR-211-5p, miR-340-5p, miR-125b-1-3p, miR-221-3p and miR-29b-3p (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3a</xref>, <italic>top row</italic>). High confidence DIANA-microT target lists also suggested differential activity for miR-100-5p across the LM-MEL cell line panel (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3a</xref>, <italic>second row</italic>).<fig id="Fig3"><label>Fig. 3</label><caption><p>
<bold>a</bold> Putative target list enrichment for individual miRs using TargetScan and DIANA-microT target lists (<italic>first and second row, respectively</italic>). Relative enrichment of combined miR target lists are also shown for GO terms associated with pigmentation or EMP. <bold>b</bold> Relationships between miR-29b-3p and LAMC1 (<italic>left</italic>), LASP1 (<italic>centre</italic>) and PPIC (<italic>right</italic>) within the LM-MEL data; for cell lines with matrigel invasiveness measurements, these data are overlaid (<italic>red, high invasiveness; blue, low invasiveness</italic>). <bold>c</bold> miR transcript abundances measured by quantitative PCR (qPCR; <italic>bar graph</italic>) for selected miRs and LM-MEL cell lines (indicated by number along the x-axis), plotted against high-throughput LM-MEL panel data (<italic>black triangles</italic>); adjusted regression coefficients between these datasets are indicated (negative for miR-211-5p due to multiple non-expressing cell lines)</p></caption><graphic xlink:href="12943_2016_554_Fig3_HTML" id="MO3"/></fig>
</p><p>The top four micro-RNAs identified have been shown previously to regulate melanoma cell proliferation, migration and/or invasiveness. As mentioned above, expression levels of miR-211 are inversely related to melanoma cell migration and invasion, and it has been shown to function as a tumour-suppressor through target genes including IGF2R, TGFBR2 (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2e</xref>) and NFAT5 [<xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR60">60</xref>]. Similarly, miR-340 downregulation promotes melanoma progression [<xref ref-type="bibr" rid="CR61">61</xref>] through de-repression of drug transporters [<xref ref-type="bibr" rid="CR62">62</xref>], RAS-RAF-MAPK signalling components [<xref ref-type="bibr" rid="CR63">63</xref>] and the key melanocytic transcription factor MITF [<xref ref-type="bibr" rid="CR64">64</xref>]. The role of miR-125b in cancer progression has also been studied extensively &#x02013; in melanoma miR-125b over-expression reduces cell proliferation and migration, mediated partly by the direct suppression of c-JUN mRNA translation [<xref ref-type="bibr" rid="CR16">16</xref>]; however, much of the literature has examined miR-125b-5p (the dominant mature form; Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3a</xref>, <italic>seventh column</italic>), rather than the -3p forms. Finally, miR-221 has a well-studied role in melanoma progression [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR65">65</xref>] and circulating miR-221 has been proposed as a melanoma biomarker [<xref ref-type="bibr" rid="CR66">66</xref>].</p></sec><sec id="Sec7"><title>Enrichment analyses implicate miR-29b-3p in melanoma phenotype switching</title><p>The role of the fifth ranked micro-RNA, miR-29b-3p, in melanoma has not yet been explored. In other cancer types, members of the miR-29a/b/c family influence EMP [<xref ref-type="bibr" rid="CR67">67</xref>&#x02013;<xref ref-type="bibr" rid="CR69">69</xref>], and act as tumour suppressors [<xref ref-type="bibr" rid="CR70">70</xref>&#x02013;<xref ref-type="bibr" rid="CR72">72</xref>]. In cutaneous melanoma, down-regulation of miR-29c has been associated with an adverse prognosis, attributed in part to its regulation of transcripts for the DNA methyltransferases DNMT3A/DNMT3B [<xref ref-type="bibr" rid="CR73">73</xref>].</p><p>Given roles for phenotype switching [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR74">74</xref>, <xref ref-type="bibr" rid="CR75">75</xref>] and pigmentation changes [<xref ref-type="bibr" rid="CR76">76</xref>] in melanoma progression, we extracted Gene Ontology database terms associated with melanogenesis or pigmentation (&#x02018;<italic>Pigmentation</italic>&#x02019;), or epithelial-mesenchymal plasticity (&#x02018;<italic>EMP</italic>&#x02019;). Next, we examined the relative enrichment of these ontological classifications within high-confidence miR target lists from TargetScan and/or DIANA-microT (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3a</xref>, <italic>at right</italic>). Consistent with its role in melanoma progression [<xref ref-type="bibr" rid="CR61">61</xref>&#x02013;<xref ref-type="bibr" rid="CR63">63</xref>], miR-340-5p had a particularly strong loading for both &#x0201c;pigmentation&#x0201d; and &#x0201c;EMP&#x0201d; categories, whilst miR-29b-3p was also enriched around 10-fold (~5.5%), providing further support that miR-29b-3p may be regulating melanoma cell invasiveness through a diverse repertoire of regulatory interactions.</p><p>TargetScan predicts hsa-miR-29-3p family-mediated regulation of Peptidylprolyl Isomerase C (Cyclophilin C; PPIC), Laminin, &#x003b3;1 (LAMC1) and LIM and SH3 Protein 1 (LASP1), and DIANA-microT also predicts miR-29b-3p regulation of LAMC1 (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1b</xref>). All three predicted targets show a strong negative association across the LM-MEL cell line panel (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3b</xref>) in a manner suggesting that reduced expression of miR-29b-3p and increased expression of these targets is associated with more invasive cell lines (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3b</xref>).</p></sec><sec id="Sec8"><title>Validation of miR and mRNA transcript abundances across a subset of LM-MEL cell lines</title><p>We performed quantitative PCR (qPCR) on selected LM-MEL cell lines to validate the high-throughput panel expression data for interactions of interest. Using miRNA-specific qPCR, transcript abundance of hsa-let-7a-5p, hsa-miR-211-5p, hsa-miR-222-3p, hsa-miR-29b-3p and hsa-miR-9-5p within total RNA showed reasonable concordance with sequencing-derived abundance data from the LM-MEL panel, and expected trends were apparent for divergent miR abundances between cell lines classified as E-like or M-like (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3c</xref>). Expression levels of target gene transcripts assessed using standard qPCR confirmed measurable levels of ATP2A2, CPEB1, TCF4, NRP1, ADAM19, CAV2, LAMC1, LASP1 and PPIC in the cell lines studied, again with trends for divergent levels between E- and M-like cell lines consistent with microarray-derived data (Figure AF5.1 within Additional file <xref rid="MOESM5" ref-type="media">5</xref>).</p></sec><sec id="Sec9"><title>hsa-miR-29b-3p regulates LAMC1, LASP1 and PPIC within several LM-MEL cell lines</title><p>As shown in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref> (panels F-H), targets of hsa-miR-29b-3p (miR-29b) include several molecules with documented roles in extracellular matrix formation, sensing, signalling or modulation, consistent with a role in invasiveness or EMT-like processes. To elucidate the role of miR-29b in melanoma invasiveness, we examined the effect of miR-29b perturbation on the transcript abundance of several putative targets in a subset of LM-MEL cell lines. Cells were transiently transfected at high efficiency with either miR-29b inhibitor or mimic (Figure AF5.2A &#x00026; B within Additional file <xref rid="MOESM5" ref-type="media">5</xref>). MiR-specific qPCR demonstrated a 2-3-log increase in detectable miR-29b levels following transfection with miR-29b mimic at 1nM (Figure AF5.2C within Additional file <xref rid="MOESM5" ref-type="media">5</xref>), whilst transfection of miR-29b inhibitor did not appreciably alter qPCR-detectable mature miR-29b abundance.</p><p>MiR-29b inhibitor treatment of the E-like cell lines LM-MEL-9 and LM-MEL-42 (high baseline levels of miR-29b) induced dose-dependent increases in transcript abundance of ADAM19, CAV2, LAMC1, PPIC, and to a lesser degree, LASP1 (Figure AF5.3 within Additional file <xref rid="MOESM5" ref-type="media">5</xref>). Treatment of the M-like cell lines LM-MEL-45, &#x02212;57 and &#x02212;77 with a miR-29b mimic markedly reduced transcript abundance of ADAM19, LAMC1, and PPIC, with more modest effects on CAV2 and LASP1 (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4a</xref> and Figure AF5.3 within Additional file <xref rid="MOESM5" ref-type="media">5</xref>). All three genes selected for further investigation (LAMC1, LASP1 and PPIC) exhibited a dose-dependent reduction in transcript level following miR-29b mimic transfection, although this effect was near-maximal at 1nM.<fig id="Fig4"><label>Fig. 4</label><caption><p>The effects of hsa-miR-29b transfection on mRNA transcript and protein levels for putative targets: LAMC1, LASP1 and PPIC. <bold>a</bold> For LM-MEL-45 and &#x02212;77 (<italic>upper and lower row, respectively</italic>), two mesenchymal-like cell lines, mRNA transcript levels were measured following transfection with hsa-miR-29b mimic. Expression has been normalised to non-transfected (NT) controls. Data represent mean&#x02009;+&#x02009;SD from independent biological duplicates performed in technical triplicates. <bold>b</bold> Representative Western blots and (<bold>c</bold>) quantified densitometry for LM-MEL-45 cell lysate harvested 96&#x000a0;h post-transfection with 10nM of miR-29b mimic, miR mimic negative control (ctrl), siRNA&#x000a0;scrambled (scram) control, or specific siRNA to the indicated mRNA target. Densitometry data represent mean&#x02009;+&#x02009;SEM signal intensities for independent triplicates normalised against a &#x003b2;-actin loading control, and shown relative to non-treated cells. Pairwise one-tailed <italic>t</italic>-test statistics are indicated by * <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, ** <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01, *** <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001. <bold>d</bold> Relationships between miR-29b-1 and miR-29b-2 (immature -3p precursors), and LAMC1 (<italic>at left</italic>) LASP1 (<italic>at centre</italic>) and PPIC (<italic>at right</italic>) within TCGA SKCM data. Pearson&#x02019;s correlations and the line of best fit are shown in <italic>red</italic>
</p></caption><graphic xlink:href="12943_2016_554_Fig4_HTML" id="MO4"/></fig>
</p><p>We assessed the effect of miR-29b overexpression on protein levels for putative targets using Western blotting for LAMC1, LASP1 and PPIC in the prototypical M-like cell line LM-MEL-45. Marked reductions in LAMC1 and PPIC protein levels were seen at 96&#x000a0;h following transient transfection with a miR-29b mimic, consistent with the effects of specific siRNAs (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4b</xref> &#x00026; <xref rid="Fig4" ref-type="fig">c</xref>). Contrasting transcript abundance changes, LASP1 protein levels were unaffected by either the miR-29b mimic or specific siRNA treatment, suggesting high protein stability and minimal LASP1 protein turnover within the duration of the assay (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4b</xref> &#x00026; <xref rid="Fig4" ref-type="fig">c</xref>).</p><p>To examine whether these putative relationships are present in vivo, we examined matched miR and mRNA transcript abundances within TCGA skin and cutaneous melanoma (SKCM) data. The abundances of mature hsa-miR-29b-1 and hsa-miR-29b-2 transcripts were examined against mRNA abundances for LAMC1, PPIC, and LASP1 (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4d</xref>). Within the TCGA data there was a relatively strong negative association between LAMC1 and miR-29b, no association between miR-29b and LASP1, and a weak negative association between miR-29b and PPIC.</p></sec><sec id="Sec10"><title>hsa-miR-29b-3p reduces melanoma cell motility and invasiveness through mechanisms beyond single-gene targets</title><p>Mild effects were observed for miR-29b-3p mimic in reducing LM-MEL-45 outgrowth survival at 21&#x000a0;days, with little change in cellular proliferation observed at 72&#x000a0;h (Figure AF5.4 &#x00026; AF5.5 within Additional file <xref rid="MOESM5" ref-type="media">5</xref>).</p><p>To better assess the effect of miR-29b on melanoma cell motility, cultured LM-MEL-45 cells were allowed to migrate into a central detection zone of the Oris plate assay system (without a chemotactic gradient) following treatment with miR-29b mimic or specific siRNA for either LAMC1 or PPIC. LASP1 was not examined on the basis that we did not demonstrate reduced levels of protein within the duration of this assay. The density of cells migrating into the central detection zone was measured after 48&#x000a0;h. Following all three treatments, LM-MEL-45 cells demonstrated a comparable reduction in migration, compared with control-treated cells (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5a</xref>).<fig id="Fig5"><label>Fig. 5</label><caption><p>Effects of miR-29b, LAMC1 and PPIC perturbation on motility and invasion of LM-MEL-45. <bold>a</bold> In the absence of a chemotactic gradient, migration of LM-MEL-45 cells into a central detection zone was decreased by treatment with a miR-29b-3p mimic, and partially phenocopied by siRNA-mediated knock-down of either LAMC1 or PPIC (data represent mean&#x02009;+&#x02009;SEM relative to controls of independent triplicates, all treatments at 10nM). <bold>b</bold> Following reverse transfection with the indicated agents (final concentrations all 10nM), and overnight culture on agarose, LM-MEL-45 spheroids were embedded into a bovine collagen type I matrix and allowed to invade over 24&#x000a0;h prior to staining with a <italic>green</italic>-fluorescent viable cell dye and imaging (representative spheroids shown). Treatment with a miR-29b-3p mimic virtually ablated any invasion of cells into surrounding collagen, whilst siRNA-mediated knockdown of PPIC led to marked invasion and/or lack of cohesion, seen as a pronounced spheroid halo. <bold>c</bold> Cross-sectional cellular density measurements of representative spheroids (see also Figure AF5.6 within Additional file <xref rid="MOESM5" ref-type="media">5</xref>) confirm relative lack of invasive cells at the spheroid surface in miR-29b-3p mimic treated cells (<italic>second panel</italic>) and, to a lesser extent, in LAMC1 knockdown cells (<italic>third panel</italic>). PPIC knockdown cells displayed a broad spheroid cell density profile consistent with extensive cellular egress into surrounding collagen (<italic>bottom panel</italic>). <bold>d</bold> Quantitation of the invasion distance from spheroid edge confirmed significant decrease in collagen invasion following miR-29b-3p overexpression, and increase following PPIC knockdown. <italic>Error bars</italic> show mean&#x02009;&#x000b1;&#x02009;SEM of at least seven spheroids per treatment</p></caption><graphic xlink:href="12943_2016_554_Fig5_HTML" id="MO5"/></fig>
</p><p>Next, spheroid collagen invasion assays were performed to compare the same treatments in a three-dimensional matrix-embedded setting. Spheroids were imaged following staining for viable cells. As predicted, miR-29b treatment reduced LM-MEL-45 cellular invasion into surrounding collagen almost entirely (representative spheroids, Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5b</xref>). Invasiveness was generally less in siRNA-treated cells, with minimal difference seen for LAMC1 knock-down. Cross-sectional cellular density profiles (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5c</xref>; <italic>method illustrated by</italic> Figure AF5.6 within Additional file <xref rid="MOESM5" ref-type="media">5</xref>) and quantitation of the collagen invasion distance (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5d</xref>) confirmed sharp transitions between relatively acellular surrounding collagen matrix and cell spheroid following miR-29b mimic and LAMC1 transfection (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5c</xref>), consistent with reduced invasion of cells into surrounding collagen.</p><p>Unexpectedly, siRNA-mediated knockdown of PPIC dramatically increased LM-MEL-45 cell invasiveness, and on cross-sectional spheroid cell density analysis, no clear transition point was observed in spheroids treated with PPIC siRNA (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5b</xref> &#x00026; <xref rid="Fig5" ref-type="fig">c</xref>), indicating diffuse cellular invasion into surrounding collagen. Within the limitations of the assay system used, it could not be determined whether this diffuse invasion of PPIC-knocked-down cells represented enhanced cellular invasiveness, decreased cell-cell cohesion, or a mixture of both processes. The effect of PPIC knockdown was opposite to that predicted following the observation that miR-29b-3p overexpression, which reduces PPIC expression, led to a decrease in spheroid collagen invasion. This contradictory effect is entirely consistent with the notion that microRNAs exert their overall observable effects through the summation of effects on multiple individual gene targets. Such individual effects may be concordant, or discordant, with the overall effect. In this case, specific PPIC knockdown appears to be pro-invasive, but when combined with the totality of perturbations induced by miR-29b-3p overexpression, the pro-invasive effect of PPIC knockdown is more than negated, leading to a net reduction in invasion. This finding demonstrates that the effects of miR-29b-3p on melanoma cell migration are not accurately replicated by perturbation of any single mRNA target in isolation.</p></sec></sec><sec id="Sec11"><title>Discussion</title><p>Integrated analysis of matched microRNA and mRNA abundance data across a large panel of melanoma cell lines identified several putative regulatory relationships influencing melanoma phenotypic plasticity. We demonstrate a novel modulatory effect for miR-29b-3p activity on melanoma cell invasiveness, most likely mediated by the combined effects on multiple gene targets. Dysregulation of miR-29b has been observed in a range of carcinomas of gastrointestinal [<xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR71">71</xref>], breast [<xref ref-type="bibr" rid="CR68">68</xref>], gynaecologic [<xref ref-type="bibr" rid="CR77">77</xref>] and prostatic origin [<xref ref-type="bibr" rid="CR78">78</xref>], with a more specific role in suppression of tumour growth and metastasis in colorectal cancer cells shown to involve blockade of epithelial-to-mesenchymal transition [<xref ref-type="bibr" rid="CR69">69</xref>]. In breast cancer models, it has been shown that miR-29b is induced by, and mediates the EMT-inhibitory effect of GATA3 via repression of tissue microenvironment remodelling factors such as MMP and VEGFA [<xref ref-type="bibr" rid="CR68">68</xref>, <xref ref-type="bibr" rid="CR79">79</xref>]. The functions of miR-29b relevant to phenotypic plasticity in melanoma remain comparatively very poorly-defined. In a study of an IFN-&#x003b3;-STAT1-miR-29 family interaction circuit, a minority of patient-derived primary melanomas were found to have markedly elevated miR-29b and miR-29a levels relative to benign nevi and normal skin, whilst metastatic samples had marginal or no elevation in miR-29a/b abundance [<xref ref-type="bibr" rid="CR80">80</xref>]. In a small panel of melanoma cell lines an inverse relationship between miR-29b level and melanoma cell line proliferation was observed, seemingly at odds with the higher miR-29a&#x02009;~&#x02009;b1 cluster abundance in some primary melanomas, and our finding that high miR-29b levels are associated with a more proliferative, epithelial-like phenotype. The confluence-based assay used to determine proliferation in the former study, together with markedly higher/combinatorial doses of miR-29 mimics/inhibitor (up to 150nM) likely contribute to these different findings.</p><p>We examined LAMC1 and PPIC in detail as potential mediators of miR-29b-3p effects across our melanoma cell models. Laminins, including LAMC1, are abundant glycoproteins within basement membranes. Consistent with our findings in melanoma, LAMC1 suppression by miR-29a/b/c has been shown to influence prostate cancer cell migration and invasion [<xref ref-type="bibr" rid="CR70">70</xref>]. PPIC, also known as cyclophilin C, is a peptidyl-prolyl <italic>cis</italic>-<italic>trans</italic> isomerase (PPIase) which influences protein folding. PPIases are substrates for cyclosporin A and may be secreted in response to cyclosporin exposure; PPIC plays a key role in endoplasmic reticulum redox homeostasis, together with PPIB [<xref ref-type="bibr" rid="CR81">81</xref>]. Little is known about PPIC in cancer, however PPIA and another PPIase PIN1 have been shown to interact with key growth and signalling proteins including cyclin D1, CDK10, cdc27, and PLK1, with diverse downstream effects on MAPK signalling [<xref ref-type="bibr" rid="CR82">82</xref>&#x02013;<xref ref-type="bibr" rid="CR85">85</xref>]. Further, PIN1 participates in EMT processes within drug-resistant breast cancer [<xref ref-type="bibr" rid="CR86">86</xref>], and drives invasiveness and tumorigenicity of A375 melanoma cells in murine models [<xref ref-type="bibr" rid="CR87">87</xref>]. PPIC has been used as a marker of circulating tumour cells (CTCs) in epithelial ovarian cancer [<xref ref-type="bibr" rid="CR88">88</xref>]. Breast cancer studies suggest a more complicated network of extracellular matrix-mitogenic signalling interactions involving PPIC, osteopontin, CD147 and AKT [<xref ref-type="bibr" rid="CR89">89</xref>], warranting further exploration in the melanoma setting given prior studies demonstrating that CD147 is a clear driver of melanoma cell proliferation and metastasis in murine models [<xref ref-type="bibr" rid="CR90">90</xref>].</p><p>The inability of LAMC1 and/or PPIC siRNA to recapitulate the effects of a miR-29b-3p mimic within the collagen spheroid assay (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5d</xref>) is likely attributable to several aspects of miR biology. Firstly, miRs have multiple potential targets but only a subset of this repertoire will be active in a given cell; for example, a miR cannot post-transcriptionally regulate a target gene that is not expressed. Secondly, the absolute abundances of miR and target gene influence the likelihood of a physical interaction, which is a pre-requisite for a regulatory interaction. Importantly, the abundances of both miR and targets may vary over time, thus creating a &#x0201c;moving network&#x0201d; of interactions. Finally, the magnitude of effect exerted by a miR on a target gene is not easily predicted and may influence the functional outcome. Taken together, these factors imply that the overall functions of a miR may be difficult to predict by perturbing any single target in isolation.</p><p>Individual miR-29b family members display variable expression patterns across tumour types and tumour stage, despite all ultimately coding for mature miRs with equivalent target repertoires [<xref ref-type="bibr" rid="CR71">71</xref>, <xref ref-type="bibr" rid="CR72">72</xref>]. This apparently independent regulation of expression of miRs from distinct genomic locations suggests that coordination of miR function may be intricately linked to the expression of other genomic features, possibly linked by transcription factor binding sites, co-location, and local epigenetic chromatin modification, all of which may combine with other regional genomic effects to produce distinct biological consequences.</p></sec><sec id="Sec12"><title>Conclusions</title><p>Two key features of micro-RNA biology are their ability to target and downregulate a large number of mRNAs [<xref ref-type="bibr" rid="CR27">27</xref>], and the ability of many micro-RNAs to target a single mRNA, resulting in a network architecture for regulatory interactions [<xref ref-type="bibr" rid="CR26">26</xref>]. We studied pairwise associations in a large panel of melanoma cell lines informed by empirical phenotypic features. A defining feature of this analysis is the examination of mutual information together with Pearson&#x02019;s correlation, allowing us to identify strong associations which may are not necessarily linear, before the principled inclusion of sequence-based miR-mRNA predicted interactions. Our approach should provide a useful framework to guide experimental work and elucidate the role of miRs in controlling cell phenotype across a number of cancers.</p><p>Our findings implicate miR-29b as a regulator of cellular phenotype in melanoma through proteins including LAMC1 and PPIC within a network of post-transcriptionally regulated genes. It is likely, however, that a complex interplay between these and other as yet undetermined miR-29b targets combine to define the overall cellular behaviours observed. Future work will focus on predicting and modelling more complex transcriptome-wide interactions. Such studies will need to address synchronous and competitive interactions, as well as sequential multi-step interactions such as those mediated by transcription factors. Experimentally validating such networks may be technically challenging, particularly under conditions simulating physiological levels of miR and mRNA transcript abundance. Nonetheless, combinatorial perturbations informed by computational modelling will enhance our understanding of summative biological effects relevant to key cell state transitions in cancer, as typified by EMP.</p></sec><sec id="Sec13"><title>Methods</title><sec id="Sec14"><title>Overview</title><p>Figure&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref> provides an illustrative overview of our analytical pipeline that integrates various data sources (Additional file <xref rid="MOESM1" ref-type="media">1</xref>), with additional technical detail given below. For the LM-MEL melanoma cell line panel [<xref ref-type="bibr" rid="CR40">40</xref>], published mRNA and novel miR transcript data were collected and processed (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6a</xref>-<xref rid="Fig6" ref-type="fig">d</xref>). Statistical associations were calculated and filtered (Fig. <xref rid="Fig6" ref-type="fig">6e</xref>-<xref rid="Fig6" ref-type="fig">f</xref>), before integrating the TargetScan [<xref ref-type="bibr" rid="CR47">47</xref>&#x02013;<xref ref-type="bibr" rid="CR49">49</xref>], DIANA-microT CDS [<xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR51">51</xref>] and miRTarBase [<xref ref-type="bibr" rid="CR91">91</xref>] databases to identify a list of putative relationships (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6g</xref>-<xref rid="Fig6" ref-type="fig">h</xref>). We examine and discuss putative miR-mRNA associations in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref> (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6i</xref>), then explore the relative enrichment of putative relationships for each miR, and the functional annotations of putative miR targets (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6j</xref>-<xref rid="Fig6" ref-type="fig">k</xref>). Phenotypic invasiveness assays for 24 cell lines were used for functional annotations associated with each putative relationship (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6l</xref>-<xref rid="Fig6" ref-type="fig">n</xref>), and TCGA melanoma samples were used to consider the potential for these associations within clinical tumour data (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6o</xref>-<xref rid="Fig6" ref-type="fig">q</xref>).<fig id="Fig6"><label>Fig. 6</label><caption><p>Computational workflow overview. <bold>a</bold> 57 melanoma cell lines derived (<bold>b</bold>) underwent mRNA and <bold>c</bold> miR transcript abundance profiling. <bold>d</bold> The data were processed and (<bold>e</bold>) measures of statistical association were calculated between miR and mRNA transcripts, across the LM-MEL panel data. <bold>f</bold> Strong, negative (inverse) associations (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1a</xref>) were filtered and (<bold>g</bold>) predicted interactions from TargetScan and/or DIANA-microT, and validated interactions from miRTarBase (<bold>h</bold>) were matched to provide a list of putative melanoma-relevant associations (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1b</xref>). <bold>i</bold> A number of interesting putative relationships were examined in further detail (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). Enrichment of (<bold>j</bold>) miR-target associations within our list, and (<bold>k</bold>) Gene Ontology annotations associated with epithelial-mesenchymal plasticity or melanogenesis/pigmentation were calculated (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3a</xref>). <bold>l</bold> Independent phenotypic (invasiveness) data were used to (<bold>m</bold>) annotate results and (<bold>n</bold>) identify putative miR-mRNA relationships which separated invasiveness groups. <bold>o</bold> Samples from the TCGA melanoma data were (<bold>p</bold>) processed and matched allowing (<bold>q</bold>) Pearson&#x02019;s correlation between miRs and mRNAs in vivo, to be calculated. <bold>r</bold> miR-29b-3p appeared to have a novel role regulating melanoma invasiveness, and several putative relationships were validated experimentally (Figs.&#x000a0;<xref rid="Fig3" ref-type="fig">3b</xref> &#x00026; <xref rid="Fig4" ref-type="fig">4</xref>). <bold>s</bold> All putative relationships are listed within Additional file <xref rid="MOESM3" ref-type="media">3</xref>. Please refer to the main text for details</p></caption><graphic xlink:href="12943_2016_554_Fig6_HTML" id="MO6"/></fig>
</p><p>Evidence suggested that miR-29b-3p influences melanoma invasiveness through regulating several mRNA transcripts (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6r</xref>), thus these putative relationships were experimentally investigated. All putative miR-mRNA relationships are listed in Additional file <xref rid="MOESM3" ref-type="media">3</xref> (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6s</xref>).</p></sec><sec id="Sec15"><title>Computational scripts</title><p>The miR-mRNA interaction pipeline for the LM-MEL data (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6d</xref>-<xref rid="Fig6" ref-type="fig">n</xref>, <xref rid="Fig6" ref-type="fig">r</xref> &#x00026; <xref rid="Fig6" ref-type="fig">s</xref>) was developed using MATLAB (R2015a) and a selection of data-processing scripts were developed using R (v3.2.3; Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6b</xref>, <xref rid="Fig6" ref-type="fig">c</xref>, <xref rid="Fig6" ref-type="fig">o</xref> &#x00026; <xref rid="Fig6" ref-type="fig">p</xref>) and python (v3.0; Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6i</xref> [TCGA plots], <xref rid="Fig6" ref-type="fig">q</xref> &#x00026; <xref rid="Fig6" ref-type="fig">r</xref>). All computational scripts developed for this project are freely available under an MIT license, from: <ext-link ext-link-type="uri" xlink:href="https://github.com/uomsystemsbiology/LMMEL-miR-miner">https://github.com/uomsystemsbiology/LMMEL-miR-miner</ext-link>
</p><p>To reproduce these results without MATLAB and extensive system configuration (e.g. installation of python packages), a Virtual Reference Environment [<xref ref-type="bibr" rid="CR92">92</xref>] is available; however, users must accept the MATLAB Compiler Runtime Libraries License displayed during installation: <ext-link ext-link-type="uri" xlink:href="https://github.com/uomsystemsbiology/LMMEL-miR-miner_reference_environment">https://github.com/uomsystemsbiology/LMMEL-miR-miner_reference_environment</ext-link>
</p></sec><sec id="Sec16"><title>LM-MEL panel mRNA data</title><p>The Ludwig Melbourne melanoma (LM-MEL) panel comprised of 57 cell lines derived from mostly metastatic melanoma tumours (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6a</xref>) has previously undergone mRNA transcript abundance profiling with the Illumina HT12 beadchip microarray platform, version 4 [<xref ref-type="bibr" rid="CR40">40</xref>]. Data were downloaded from ArrayExpress (Additional file <xref rid="MOESM1" ref-type="media">1</xref>) and underwent background correction, quantile normalisation and log<sub>2</sub>-transformation within R, retaining multiple probes as distinct observations (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6b</xref>).</p></sec><sec id="Sec17"><title>LM-MEL panel miR data</title><p>MicroRNA profiling was performed across the LM-MEL panel of cell lines by small RNA sequencing at the Australian Genome Research Facility (AGRF) on the Illumina HiSeq platform using total RNA, including small RNAs, purified from cell line pellets using the Qiagen miRNEasy isolation kit, following the manufacturer&#x02019;s recommendations (Qiagen, Chadstone, Victoria, Australia). Library preparation and 5&#x02019;-barcode multiplexing were performed prior to sequencing; each sample was run in 3&#x02013;4 sequencing lanes as required to achieve adequate sequencing depth. Initial read quality assessment and filtering were performed by AGRF. De-multiplexed raw read data and quality scores were provided in fastq format. All reads for each sample were concatenated using the UNIX command line and collapsed to single fasta format files using the FASTX-Toolkit (v. 0.0.13) command-line tool FASTQ Collapser. Collapsed reads were processed through the miRanalyzer webserver [<xref ref-type="bibr" rid="CR93">93</xref>] to map reads to the genome using the hg18 build of the UCSC <italic>Homo sapiens</italic> genome, followed by mapping of miRs to miRBase [<xref ref-type="bibr" rid="CR94">94</xref>&#x02013;<xref ref-type="bibr" rid="CR99">99</xref>]. Raw and processed miR abundance data were deposited on the Gene Expression Omnibus (GEO;&#x000a0;dataset GSE89438; Additional file <xref rid="MOESM1" ref-type="media">1</xref>). These data underwent normalisation and a log<sub>2</sub>-transformation was performed (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6c</xref>).</p></sec><sec id="Sec18"><title>LM-MEL phenotypic invasiveness data</title><p>Invasiveness through matrigel-coated Boyden chambers (8&#x000a0;&#x003bc;m pore size) was profiled for 24 LM-MEL cell lines (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6l</xref>); cell lines were subsequently grouped as high- or low-invasiveness (Additional file <xref rid="MOESM1" ref-type="media">1</xref>) and used for annotation (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6m</xref>) and further analysis (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6n</xref>).</p></sec><sec id="Sec19"><title>TCGA miR and mRNA data</title><p>Matched miR and mRNA sequencing data from TCGA skin cutaneous melanoma samples were downloaded (Additional file <xref rid="MOESM1" ref-type="media">1</xref>), comprised of 368 samples from 366 individual patients (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6o</xref>). R scripts were developed to use the dataset&#x02019;s native directory structure for extracting and compiling normalised mature microRNA isoform read counts (including &#x02018;star&#x02019; [*] forms), and RNAseq normalised read counts from all samples (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6p</xref>). Samples were matched across the microRNA and RNA data according to the unique TCGA patient/sample barcodes.</p></sec><sec id="Sec20"><title>LM-MEL data pre-processing</title><p>To reduce the computational burden of the statistical analysis, the LM-MEL mRNA and miR abundance data were pre-processed (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6d</xref>) to remove RNAs with a very low abundance or dynamic range, as these features can indicate a poor signal-to-noise ratio for the data. The 10<sup>th</sup>-percentiles of mRNA and miR abundance were identified, and any miRs or mRNAs with less than 25% of observations (i.e. across the 14/57 cell lines) above their respective thresholds were excluded. Similarly, miRs which did not have a range greater than the 90<sup>th</sup> percentile of the miR abundance data and mRNA probes which did not have a range greater than 10% of the total mRNA data range, were also filtered. This pre-processing retained 198/2592 miRs (note that 916 of the miRs had no reads across any cell line) and 16482/47231 mRNA probes within the LM-MEL data.</p></sec><sec id="Sec21"><title>Statistical associations</title><p>Pearson&#x02019;s correlation and mutual information were calculated between miR and mRNA abundance, across all pairwise combinations of miRs and mRNAs which passed pre-processing (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6e</xref>). The intrinsic &#x02018;<italic>corr</italic>&#x02019; function within MATLAB (R2015a; Statistics and Machine Learning Toolbox) was used to calculate the Pearson&#x02019;s correlation.</p><p>As noted earlier, mutual information is a measure of statistical association which is formulated such that it will tend towards zero in the case of statistical independence between the miR and mRNA abundance. Mutual information was calculated using the Java Information Dynamics Toolkit (JIDT) [<xref ref-type="bibr" rid="CR43">43</xref>] with the &#x02018;multivariate Kraskov 2 estimator&#x02019; (i.e. miR and mRNA transcript abundance data were treated as continuous variables and the Kraskov-Stoegbauer-Grassberger estimator was used to calculate the MI), implemented within the MATLAB Network Analysis and Inference Libraries [<xref ref-type="bibr" rid="CR42">42</xref>]. Note that the JIDT corrects for mutual information over-estimation [<xref ref-type="bibr" rid="CR46">46</xref>], and this subtraction can lead to negative mutual information values (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1a</xref> &#x00026; <xref rid="Fig1" ref-type="fig">b</xref>).</p><p>For the TCGA data analysed within python, correlations were calculated (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6q</xref>) using the numpy package [<xref ref-type="bibr" rid="CR100">100</xref>] and plots (Figs.&#x000a0;<xref rid="Fig6" ref-type="fig">6I</xref> &#x00026; 7r) were produced using the matplotlib package [<xref ref-type="bibr" rid="CR101">101</xref>].</p><p>Under the hypothesis that miR-mediated degradation of target mRNA transcripts would manifest as a negative association, we filtered for the top 10% of associations when ranked by mutual information (mutual information&#x02009;&#x0003e;&#x02009;0.259), and the most negative 2.5% of associations when ranked by Pearson&#x02019;s correlation (Pearson&#x02019;s correlation&#x02009;&#x0003c;&#x02009;&#x02212;0.330; Figs.&#x000a0;<xref rid="Fig1" ref-type="fig">1a</xref> &#x00026; 7f).</p></sec><sec id="Sec22"><title>Databases</title><p>Ensembl BioMart [<xref ref-type="bibr" rid="CR102">102</xref>] was used to match identifiers between different databases as necessary. To reduce the search domain of putative interactions and filter indirect associations which may arise through the modulation of an intermediate regulatory component (e.g. a transcription factor), we filtered for predicted miR-mRNA relationships with a relatively high confidence. Specifically, we took the top 15<sup>th</sup> percentile of TargetScan v7.0 (context&#x02009;+&#x02009;score&#x02009;&#x0003c;&#x02009;&#x02212;0.286) [<xref ref-type="bibr" rid="CR47">47</xref>&#x02013;<xref ref-type="bibr" rid="CR49">49</xref>], and/or the top 30<sup>th</sup> percentile of DIANA-microT CDS (miTG-score&#x02009;&#x0003e;&#x02009;0.634) [<xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR51">51</xref>] (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6g</xref>). The miR-mRNA relationships which had been experimentally validated with &#x02018;strong evidence&#x02019; on miRTarBase [<xref ref-type="bibr" rid="CR91">91</xref>] (&#x02018;Luciferase reporter assay&#x02019;; 'qRT-PCR' or 'Western blot') were also extracted (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6g</xref>) and used to annotate the selected statistical associations. This allowed us to identify a set of putative miR-mRNA relationships (Figs.&#x000a0;<xref rid="Fig1" ref-type="fig">1b</xref> &#x00026; 7&#x000a0;h) which may show graded levels of activity across different melanoma samples, contributing to differences in cell phenotype.</p><p>Micro-RNAs can regulate large phenotypic changes through distributed regulation of targets with a related function [<xref ref-type="bibr" rid="CR27">27</xref>]. Annotations were downloaded from the Gene Ontology [<xref ref-type="bibr" rid="CR103">103</xref>] database [<xref ref-type="bibr" rid="CR104">104</xref>] (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6k</xref>) and mRNAs were matched to GO annotations using strings related to epithelial-mesenchymal plasticity (&#x02018;epith&#x02019;,&#x02019;mesench&#x02019;) or pigmentation/melanogenesis (&#x02018;pigment&#x02019;, &#x02018;melan&#x02019;; Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6j</xref>, <italic>at bottom</italic>). GO categories were excluded if they had less than 5, or more than 500, gene members, and all categories are listed in Additional file <xref rid="MOESM6" ref-type="media">6</xref>.</p></sec><sec id="Sec23"><title>Invasiveness-separation metric</title><p>A metric was created to quantify the relative separation of low- and high-invasive cell line groups over the miR abundance ([miR]) versus mRNA abundance ([mRNA]) association (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6n</xref>). Calculating the centroid/geometric mean of the low- <inline-formula id="IEq2"><alternatives><tex-math id="M3">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ \left({\widehat{\mu}}_{miR, low},\;{\widehat{\mu}}_{mRNA, low}\right) $$\end{document}</tex-math><mml:math id="M4"><mml:mfenced close=")" open="("><mml:mrow><mml:msub><mml:mover accent="true"><mml:mi>&#x003bc;</mml:mi><mml:mo stretchy="true">^</mml:mo></mml:mover><mml:mrow><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>R</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="italic">low</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mspace width="0.12em"/><mml:msub><mml:mover accent="true"><mml:mi>&#x003bc;</mml:mi><mml:mo stretchy="true">^</mml:mo></mml:mover><mml:mrow><mml:mi mathvariant="italic">mRNA</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="italic">low</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:math><inline-graphic xlink:href="12943_2016_554_Article_IEq2.gif"/></alternatives></inline-formula> and high-invasive <inline-formula id="IEq3"><alternatives><tex-math id="M5">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ \left({\widehat{\mu}}_{miR, high},\;{\widehat{\mu}}_{mRNA, high}\right) $$\end{document}</tex-math><mml:math id="M6"><mml:mfenced close=")" open="("><mml:mrow><mml:msub><mml:mover accent="true"><mml:mi>&#x003bc;</mml:mi><mml:mo stretchy="true">^</mml:mo></mml:mover><mml:mrow><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>R</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="italic">high</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mspace width="0.12em"/><mml:msub><mml:mover accent="true"><mml:mi>&#x003bc;</mml:mi><mml:mo stretchy="true">^</mml:mo></mml:mover><mml:mrow><mml:mi mathvariant="italic">mRNA</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="italic">high</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:math><inline-graphic xlink:href="12943_2016_554_Article_IEq3.gif"/></alternatives></inline-formula> groups from mRNA and miR abundances, we defined:<disp-formula id="Equa"><alternatives><tex-math id="M7">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ {d}_{Sep, \max }=\sqrt{{\left( \max \left(\left[ mRNA\right]\right)- \min \left(\left[ mRNA\right]\right)\right)}^2+{\left( \max \left(\left[miR\right]\right)- \min \left(\left[miR\right]\right)\right)}^2} $$\end{document}</tex-math><mml:math id="M8"><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>e</mml:mi><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:mo>max</mml:mo></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msqrt><mml:mrow><mml:msup><mml:mfenced close=")" open="("><mml:mrow><mml:mo>max</mml:mo><mml:mfenced close=")" open="("><mml:mfenced close="]" open="["><mml:mi mathvariant="italic">mRNA</mml:mi></mml:mfenced></mml:mfenced><mml:mo>&#x02212;</mml:mo><mml:mo>min</mml:mo><mml:mfenced close=")" open="("><mml:mfenced close="]" open="["><mml:mi mathvariant="italic">mRNA</mml:mi></mml:mfenced></mml:mfenced></mml:mrow></mml:mfenced><mml:mn>2</mml:mn></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mfenced close=")" open="("><mml:mrow><mml:mo>max</mml:mo><mml:mfenced close=")" open="("><mml:mfenced close="]" open="["><mml:mrow><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:mfenced></mml:mfenced><mml:mo>&#x02212;</mml:mo><mml:mo>min</mml:mo><mml:mfenced close=")" open="("><mml:mfenced close="]" open="["><mml:mrow><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:mfenced></mml:mfenced></mml:mrow></mml:mfenced><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:msqrt></mml:math><graphic xlink:href="12943_2016_554_Article_Equa.gif" position="anchor"/></alternatives></disp-formula>
<disp-formula id="Equb"><alternatives><tex-math id="M9">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ {d}_{Sep, norm}=\frac{\sqrt{{\left({\widehat{\mu}}_{nRNA, high}-{\widehat{\mu}}_{mRNA, low}\right)}^2+{\left({\widehat{\mu}}_{miR, high}-{\widehat{\mu}}_{miR, low}\right)}^2}}{d_{Sep, \max }} $$\end{document}</tex-math><mml:math id="M10"><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>e</mml:mi><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="italic">norm</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:msqrt><mml:mrow><mml:msup><mml:mfenced close=")" open="("><mml:mrow><mml:msub><mml:mover accent="true"><mml:mi>&#x003bc;</mml:mi><mml:mo stretchy="true">^</mml:mo></mml:mover><mml:mrow><mml:mi mathvariant="italic">nRNA</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="italic">high</mml:mi></mml:mrow></mml:msub><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>&#x003bc;</mml:mi><mml:mo stretchy="true">^</mml:mo></mml:mover><mml:mrow><mml:mi mathvariant="italic">mRNA</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="italic">low</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced><mml:mn>2</mml:mn></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mfenced close=")" open="("><mml:mrow><mml:msub><mml:mover accent="true"><mml:mi>&#x003bc;</mml:mi><mml:mo stretchy="true">^</mml:mo></mml:mover><mml:mrow><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>R</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="italic">high</mml:mi></mml:mrow></mml:msub><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>&#x003bc;</mml:mi><mml:mo stretchy="true">^</mml:mo></mml:mover><mml:mrow><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>R</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="italic">low</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:msqrt><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>e</mml:mi><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:mo>max</mml:mo></mml:mrow></mml:msub></mml:mfrac></mml:math><graphic xlink:href="12943_2016_554_Article_Equb.gif" position="anchor"/></alternatives></disp-formula>
</p><p>The percentile rank of d<sub>Sep,norm</sub> was calculated for all miR-mRNA associations, where the miR and mRNA association passed the data pre-processing, and is listed with corresponding relationships within Additional file <xref rid="MOESM3" ref-type="media">3</xref>.</p></sec><sec id="Sec24"><title>Cell line culture</title><p>Melanoma cell lines were obtained from institutional stocks, as previously described [<xref ref-type="bibr" rid="CR40">40</xref>]. LM-MEL-7, &#x02212;9, &#x02212;42, &#x02212;45 and &#x02212;77 were used for in vitro experiments; identity was confirmed by STR profiling and HLA-matching to the documented patient of origin. All cell lines were maintained in adherent culture incubated in 5% atmospheric CO<sub>2</sub> at 37&#x000b0;C in RPMI 1640 media (Gibco&#x000ae;, Life Technologies&#x02122;, Mulgrave VIC, Australia) supplemented with 10% fetal bovine serum (Sigma, St Louis MO, USA), 1% glutamine (glutaMAX&#x02122;) and 1% penicillin/streptomycin (both from Gibco&#x000ae;, Life Technologies&#x02122;).</p></sec><sec id="Sec25"><title>Transient transfections with miR inhibitor/mimic or siRNA</title><p>Cells were seeded into 6, 12 or 96 well plates as required for planned downstream assays. Transfections were performed when cells were approximately 70% confluent, using the Lipofectamine&#x000ae; RNAiMAX transfection reagent (Invitrogen&#x02122;, Life Technologies&#x02122;) at 0.3, 2 or 3&#x000a0;&#x003bc;L per well of 96, 12 or 6 well plates, respectively, diluted in OptiMEM&#x000ae; reduced serum medium (Gibco&#x000ae;, Life Technologies&#x02122;) and mixed 1:1 with microRNA/siRNA construct (also in OptiMEM&#x000ae;) to a final volume producing a 1:5 final dilution into growth media. For microRNA transfections, cells were forward transfected with mirVana&#x02122; miRNA inhibitor negative control #1 or miRNA-29b-3p inhibitor, miRNA mimic negative control #1 or miRNA-29b-3p mimic (all Ambion&#x02122;, Life Technologies&#x02122;, Cat. Nos. 4464076, 4464084, 4464058, 4464066) at final concentrations as indicated in results. For gene target knockdown studies, cells were transfected with siRNA scrambled control or specific siRNAs targeting LAMC1, LASP1 or PPIC (all OriGene Trilencer-27 Human siRNA, Cat. Nos. SR30004, SR302649, SR302655, SR303664; Rockville, MD, USA), at doses indicated in results. For spheroid assays, cells were reverse transfected using identical reagent mixtures at the time of seeding onto agar.</p></sec><sec id="Sec26"><title>Real time-PCR</title><p>Total RNA was collected from treated/untreated cell pellets using RNeasy (standard gene qPCR only) or miRNeasy (total RNA including small RNA) kits (Qiagen, Melbourne, Victoria, Australia) and cDNA formed using the high-capacity cDNA reverse transcription kit (Applied Biosystems&#x02122;, Life Technologies&#x02122;, Cat. No. 4368814) or TaqMan&#x000ae; microRNA reverse transcription kit (Cat. No. 4366596), respectively, according to the manufacturer&#x02019;s protocol. MicroRNA qPCR was performed using TaqMan&#x000ae; Universal PCR Master Mix, no AmpErase&#x000ae; UNG (Cat. No. 4324018) and TaqMan&#x000ae; microRNA assays (all Cat. No. 4427975) specific for hsa-miR-211 (ID 000514), hsa-miR-125b-1* (ID 002378), hsa-miR-221* (ID 002096), hsa-miR-9 (ID 000583), hsa-miR-23b (ID 000400), hsa-miR-29b (ID 000413), hsa-miR-222 (ID 002276), hsa-let-7a (ID 000377), or controls RNU44 (ID 001094) and RNU24 (ID 001001). Target gene qPCR was performed using SensiFAST&#x02122; SYBR&#x000ae; Lo-ROX mastermix (Bioline, Alexandria, NSW, Australia) with PCR primers designed as per Table AF5.1 in Additional file <xref rid="MOESM5" ref-type="media">5</xref>.</p><p>Data were collected as &#x02206;&#x02206;CT with melt curve inspection using the ViiA&#x02122; 7 Real-Time PCR System and accompanying software (Applied Biosystems&#x02122;, Life Technologies&#x02122;) based on technical triplicates. Mean CT from 2 to 3 biological replicates was expressed as copies per 10,000 copies of a reference gene (&#x003b2;-actin, RNU24 or RNU44).</p></sec><sec id="Sec27"><title>In vitro proliferation assays</title><p>Cells were seeded at 5000 cells per well in flat-bottomed 96-well tissue culture plates prior to transfection with microRNA or siRNA agents as described above. Cellular proliferation was measured at baseline (i.e. pre-transfection) and at 24 and 72&#x000a0;h following transfection by incubation for 1.5&#x000a0;h in MTS reagent (CellTiter 96&#x000ae; AQueous One Solution Cell Proliferation Assay, Promega, Madison WI, USA) diluted 1 in 6 in culture media, followed by measurement of the absorbance at 490&#x000a0;nm and background correction using a no-cell control.</p></sec><sec id="Sec28"><title>Low-density seeding assays</title><p>Transfected cells were re-harvested and plated in 6-well tissue-culture treated plates at a density of 2000 cells per well, in 2&#x000a0;mL culture medium. Cells were monitored visually each day and allowed to grow for 21&#x000a0;days prior to fixation in 2% paraformaldehyde (Electron Microscopy Sciences, Hatfield, PA, USA) and staining with 0.01% crystal violet/10% ethanol. Plates were imaged in the 680&#x000a0;nm infrared channel using the Odyssey scanner (LI-COR&#x000ae; Biosciences, Lincoln, NE, USA) prior to subsequent quantitation of cellular outgrowth using the Colony Area plugin for ImageJ&#x000a0;(version 1.47) [<xref ref-type="bibr" rid="CR105">105</xref>, <xref ref-type="bibr" rid="CR106">106</xref>].</p></sec><sec id="Sec29"><title>Western blotting</title><p>Protein was harvested from cells 96&#x000a0;h following transient transfection with miR-29b agents or specific siRNAs against LAMC1, LASP1 or PPIC. Cell lysates were prepared in 100&#x000a0;&#x003bc;L of RIPA buffer (Thermo Scientific&#x02122; Pierce&#x02122;, Cat. No. 89900) containing the manufacturer&#x02019;s recommended concentrations of PhosSTOP&#x02122; phosphatase inhibitor and cOmplete&#x02122; ULTRA EDTA-free protease inhibitor (Roche Diagnostics GmbH, Mannheim, Germany), incubated for 30&#x000a0;min at 4&#x000b0;C prior to manual scraping of cells/lysates. Protein concentrations were estimated using the BCA method (Thermo Scientific&#x02122; Pierce&#x02122; BCATM Protein Assay Kit, Cat#23225) as per the manufacturer&#x02019;s directions. Samples were immediately adjusted to uniform final concentrations by the addition of extra lysis buffer as required, prior to the addition of NuPAGE&#x000ae; LDS Sample Buffer (4&#x000d7;) and NuPAGE&#x000ae; sample reducing agent (10&#x000d7;) (both from Novex&#x000ae;, Life Technologies, Cat#NP008 and Cat#NP009). Samples were electrophoresed on NuPAGE&#x000ae; Novex&#x000ae; Bis-Tris 4&#x02013;12% pre-cast gels prior to transfer to nitrocellulose membrane using the iBlot&#x000ae; Dry Blotting System (Invitrogen&#x02122;, Life Technologies, Mulgrave, Victoria, Australia). Membranes were blocked in Odyssey Blocking Buffer (LI-COR&#x000ae; Biosciences) for 1&#x000a0;h at room temperature before probing for LAMC1 (apparent MW 178&#x000a0;kDa) using the rabbit anti-laminin gamma 1 monoclonal antibody RabMab [EPR8217] (Abcam, Cat. No. ab134059; Melbourne, Victoria, Australia) at 1:1000, for LASP1 (apparent MW 30&#x000a0;kDa) using the rabbit polyclonal anti-LASP1 &#x02013; N-terminal antibody (Abcam, Cat. No. ab191022) at 1:1000, or for PPIC using the rabbit monoclonal anti-PPIC &#x02013; C-terminal antibody RabMab [EPR15355] (Abcam, Cat. No. ab184552) at 1:10,000. Loading was controlled to &#x003b2;-Actin (apparent MW 45&#x000a0;kDa) using the mouse monoclonal anti-&#x003b2;-Actin (8H10D10) antibody (Cell Signaling Technology, Cat. No. 3700; Danvers, MA, USA) at 1:3000. Membranes were incubated with primary antibodies for 2&#x000a0;h at room temperature in a 1:1 mixture of PBS containing 0.05% tween-20 (PBST) and Odyssey Blocking Buffer. Bands were visualised by staining with IRDye&#x000ae; 680RD goat anti-mouse IgG and IRDye&#x000ae; 800CW goat anti-rabbit IgG secondaries at 1:40,000 and 1:20,000 respectively (LI-COR&#x000ae;, Prod. Nos. 926&#x02013;68070 and 926&#x02013;32211) for 1&#x000a0;h at room temperature. Air-dried membranes were scanned on the LI-COR&#x000ae; ODYSSEY&#x000ae; Infrared Imaging System and densitometry performed in the Image Studio&#x02122; Lite Version 5.0 software (LI-COR&#x000ae;). Densitometry results were normalized to &#x003b2;-Actin and expressed relative to the appropriate control treatment.</p></sec><sec id="Sec30"><title>Undirected radial migration assays</title><p>Transfected cells were re-harvested, counted and delivered at 40,000 cells per well of 96 well optical-bottom plates (Nunc, ThermoFisher Scientific) fitted with Oris&#x02122; Cell Migration Assay stoppers (Platypus Technologies, Madison, WI, USA). Cells were allowed to adhere overnight prior to removal of stoppers, leaving a 2&#x000a0;mm diameter detection zone in the centre of each well. After changing to fresh growth media, cells were allowed to migrate for 24&#x02013;48&#x000a0;h prior to fixation in 2% paraformaldehyde and staining with 0.01% crystal violet/10% ethanol.</p></sec><sec id="Sec31"><title>Spheroid collagen invasion assays</title><p>Collagen-implanted spheroid invasion was performed based on previously-described methods [<xref ref-type="bibr" rid="CR107">107</xref>]. Spheroids were prepared by seeding 150,000 cells in 2&#x000a0;mL of growth medium (with required transfection reagents) into wells of six well plates on top of pre-formed 0.8% agarose base-layers (Sigma, Cat. No. A9539) diluted from sterilised 3.2% agarose stock with growth medium. After 48&#x000a0;h incubation, spheroids were harvested by gentle aspiration, transferred to sterile collection tubes and allowed to settle by gravity for 30&#x000a0;min prior to manual aspiration of overlying media. Neutralised collagen was prepared from 5&#x000a0;mg/mL bovine collagen type I stock (Trevigen Cultrex&#x000ae;, Cat. No. 3442-050-01, Gaithersberg, MD, USA) by dilution 1:1 with 2&#x000d7; growth medium (2&#x000d7; RPMI 1640, 20% FBS) and pH adjusted by dropwise addition of sterile 1&#x000a0;M NaOH. Acellular collagen base layers were prepared by aliquoting 300&#x000a0;&#x003bc;L of neutralised collagen into wells of a 24 well plate and allowed to gel at room temperature for 30&#x000a0;min. Spheroids were then gently resuspended in 500&#x000a0;&#x003bc;L of neutralised collagen diluted 2:1 with 1&#x000d7; growth medium (final collagen concentration 1.67&#x000a0;mg/mL) and overlaid onto base layers and allowed to gel for 10&#x000a0;min at room temperature before returning to the incubator. Once completely gelled, collagen was overlaid with a further 500&#x000a0;&#x003bc;L of growth media. Spheroids were allowed to invade for 24&#x000a0;h prior to fluorescent viability staining with calcein-AM (live) and EthD-III (dead) using the Live/Dead Cell Staining Kit II (PromoKine, Cat. No. PK-CA707-30002, PromoCell GmbH, Heidelberg, Germany) before imaging.</p></sec></sec></body><back><app-group><app id="App1"><sec id="Sec32"><title>Additional files</title><p>
<media position="anchor" xlink:href="12943_2016_554_MOESM1_ESM.docx" id="MOESM1"><label>Additional file 1:</label><caption><p>Data and Computational Tools (.docx) &#x02013; Contains <bold>Table AF1.1</bold>, which lists detailed information on the data and computational tools used in this study. (DOCX 14&#x000a0;kb)</p></caption></media>
<media position="anchor" xlink:href="12943_2016_554_MOESM2_ESM.csv" id="MOESM2"><label>Additional file 2:</label><caption><p>Table (.csv) of matrigel invasiveness (classified as invasive/non-invasive) for LM-MEL cell lines which is read into the computational scripts. For details on the experimental protocol please refer to <xref rid="Sec13" ref-type="sec">Methods</xref>/<xref rid="Sec18" ref-type="sec">LM-MEL phenotypic invasiveness data</xref>. (CSV 273 bytes)</p></caption></media>
<media position="anchor" xlink:href="12943_2016_554_MOESM3_ESM.csv" id="MOESM3"><label>Additional file 3:</label><caption><p>Table (.csv) output from the computational scripts containing (1041) putative relationships with a strong negative statistical association and support from TargetScan and/or DIANA-microT, or mirTarBase (i.e. the full list of associations from Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1b</xref>). mRNA Transcripts which have been annotated with a role in pigmentation or EMP via their GO category (from Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1c</xref>) are labelled. mRNA transcripts which have been previously implicated in phenotypic switching in melanoma are labelled [<xref ref-type="bibr" rid="CR3">3</xref>]. (CSV 77&#x000a0;kb)</p></caption></media>
<media position="anchor" xlink:href="12943_2016_554_MOESM4_ESM.docx" id="MOESM4"><label>Additional file 4:</label><caption><p>miRNA-mRNA Interactions of Interest (.docx) &#x02013; Contains: <bold>Table AF4.1</bold>, which lists miRNA-mRNA interactions identified from our analysis that have been previously validated in human cellular contexts. <bold>Table AF4.2</bold>, which lists novel putative miRNA-mRNA interactions that involve mRNA transcripts implicated in melanoma EMP behaviours and/or invasiveness. (DOCX 86&#x000a0;kb)</p></caption></media>
<media position="anchor" xlink:href="12943_2016_554_MOESM5_ESM.pdf" id="MOESM5"><label>Additional file 5:</label><caption><p>Supporting Experimental Data (.pdf) &#x02013; Contains: <bold>Table AF5.1</bold>, which lists the PCR primers used. <bold>Figure AF5.1</bold> which displays baseline expression for genes of interest in a subset of LM-MEL melanoma cell lines using qPCR. <bold>Figure AF5.2</bold>, which displays siRNA transfection efficiency; <bold>Figure AF5.3</bold>, which displays additional qPCR results showing the effects of miR-29b mimic/inhibitor transfection. <bold>Figure AF5.4 &#x00026; AF5.5</bold>, which display the effects of miR-29b mimic/inhibitor transfection on LM-MEL-77 cell proliferation and outgrowth. <bold>Figure AF5.6</bold>, which displays information to aid the reader&#x02019;s interpretation of melanoma spheroid data. (PDF 3182&#x000a0;kb)</p></caption></media>
<media position="anchor" xlink:href="12943_2016_554_MOESM6_ESM.csv" id="MOESM6"><label>Additional file 6:</label><caption><p>Table (.csv) of Gene Ontology (GO) database terms used for the enrichment analysis of &#x02018;epithelial-mesenchymal plasticity&#x02019; (EMP) and pigmentation processes in Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3a</xref>, together with the number of genes within each category. As detailed in <xref rid="Sec13" ref-type="sec">Methods</xref>/<xref rid="Sec22" ref-type="sec">Databases</xref>, terms were identified by string matching and GO terms were excluded if they had less than five or more than 500 member genes. (CSV 5&#x000a0;kb)</p></caption></media>
</p></sec></app></app-group><glossary><title>Abbreviations</title><def-list><def-item><term>CTCs</term><def><p>Circulating tumour cells</p></def></def-item><def-item><term>EMP</term><def><p>Epithelial-mesenchymal plasticity</p></def></def-item><def-item><term>EMT</term><def><p>Epithelial-to-mesenchymal (like) transition</p></def></def-item><def-item><term>LAMC1</term><def><p>Laminin, &#x003b3;1 (Entrez Gene ID 3915)</p></def></def-item><def-item><term>LASP1</term><def><p>LIM and SH3 Protein 1 (Entrez Gene ID 3927)</p></def></def-item><def-item><term>LM-MEL</term><def><p>Ludwig Melbourne melanoma cell line</p></def></def-item><def-item><term>miR</term><def><p>microRNA</p></def></def-item><def-item><term>miR-29b</term><def><p>hsa-miR-29b-3p (miRBase Accession: MIMAT0000100)</p></def></def-item><def-item><term>PPIC</term><def><p>Peptidylprolyl Isomerase C (Cyclophilin C; Entrez Gene ID 5480)</p></def></def-item><def-item><term>TCGA</term><def><p>The Cancer Genome Atlas</p></def></def-item></def-list></glossary><ack><title>Acknowledgements</title><p>The authors would like to acknowledge researchers who have established and maintain the databases (Additional file <xref rid="MOESM1" ref-type="media">1</xref>) which make this analysis feasible. The results published here are in part based upon data generated by the TCGA Research Network: <ext-link ext-link-type="uri" xlink:href="http://cancergenome.nih.gov/">http://cancergenome.nih.gov/</ext-link>.</p><p>JC would like to thank: Dr C Bracken at the Centre for Cancer Biology, University of South Australia, for his advice on the computational analysis and for providing feedback on the manuscript.</p><sec id="FPar1"><title>Funding</title><p>MCA is supported by a Postgraduate Medical Scholarship from the National Health and Medical Research Council of Australia (#1055456). This work was funded in part by: Ludwig Cancer Research; the Operational Infrastructure Support Program of the Victorian State Government; and the Australian Research Council Centre of Excellence in Convergent Bio-Nano Science and Technology (project number CE140100036).</p></sec><sec id="FPar2"><title>Availability of data and materials</title><p>All data used in this study are included within the article and additional files, or made freely available within repositories as specified in Additional file <xref rid="MOESM1" ref-type="media">1</xref>.</p></sec><sec id="FPar3"><title>Authors' contributions</title><p>MCA carried out gene and microRNA expression analysis, data processing, and interpretation, in vitro validation studies, and drafting of the manuscript. JC performed transcriptomic analysis, data integration, systems analysis and interpretation, and drafting of the manuscript. DGH participated in transcriptomic and systems analysis and interpretation, and drafting of the manuscript. MA participated in sample acquisition, and generating primary mRNA/microRNA abundance data. AB participated in sample acquisition, cell line and primary data generation, transcriptomic data interpretation, in vitro studies and phenotypic assays. JSC was involved in sample acquisition. JSC and EC participated in data interpretation. All authors were involved in study conception and design, and have read and approved the final manuscript.</p></sec><sec id="FPar4"><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec id="FPar5"><title>Consent for publication</title><p>Not applicable.</p></sec><sec id="FPar6"><title>Ethics approval and consent to participate</title><p>Not applicable.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zipser</surname><given-names>MC</given-names></name><name><surname>Eichhoff</surname><given-names>OM</given-names></name><name><surname>Widmer</surname><given-names>DS</given-names></name><name><surname>Schlegel</surname><given-names>NC</given-names></name><name><surname>Schoenewolf</surname><given-names>NL</given-names></name><name><surname>Stuart</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Gardner</surname><given-names>H</given-names></name><name><surname>Smith</surname><given-names>PD</given-names></name><name><surname>Nuciforo</surname><given-names>P</given-names></name><etal/></person-group><article-title>A proliferative melanoma cell phenotype is responsive to RAF/MEK inhibition independent of BRAF mutation status</article-title><source>Pigment Cell Melanoma Res</source><year>2011</year><volume>24</volume><fpage>326</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1111/j.1755-148X.2010.00823.x</pub-id><?supplied-pmid 21176117?><pub-id pub-id-type="pmid">21176117</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoek</surname><given-names>KS</given-names></name><name><surname>Eichhoff</surname><given-names>OM</given-names></name><name><surname>Schlegel</surname><given-names>NC</given-names></name><name><surname>Dobbeling</surname><given-names>U</given-names></name><name><surname>Kobert</surname><given-names>N</given-names></name><name><surname>Schaerer</surname><given-names>L</given-names></name><name><surname>Hemmi</surname><given-names>S</given-names></name><name><surname>Dummer</surname><given-names>R</given-names></name></person-group><article-title>In vivo switching of human melanoma cells between proliferative and invasive states</article-title><source>Cancer Res</source><year>2008</year><volume>68</volume><fpage>650</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-2491</pub-id><?supplied-pmid 18245463?><pub-id pub-id-type="pmid">18245463</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Widmer</surname><given-names>DS</given-names></name><name><surname>Cheng</surname><given-names>PF</given-names></name><name><surname>Eichhoff</surname><given-names>OM</given-names></name><name><surname>Belloni</surname><given-names>BC</given-names></name><name><surname>Zipser</surname><given-names>MC</given-names></name><name><surname>Schlegel</surname><given-names>NC</given-names></name><name><surname>Javelaud</surname><given-names>D</given-names></name><name><surname>Mauviel</surname><given-names>A</given-names></name><name><surname>Dummer</surname><given-names>R</given-names></name><name><surname>Hoek</surname><given-names>KS</given-names></name></person-group><article-title>Systematic classification of melanoma cells by phenotype-specific gene expression mapping</article-title><source>Pigment Cell Melanoma Res</source><year>2012</year><volume>25</volume><fpage>343</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1111/j.1755-148X.2012.00986.x</pub-id><?supplied-pmid 22336146?><pub-id pub-id-type="pmid">22336146</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramsdale</surname><given-names>R</given-names></name><name><surname>Jorissen</surname><given-names>RN</given-names></name><name><surname>Li</surname><given-names>FZ</given-names></name><name><surname>Al-Obaidi</surname><given-names>S</given-names></name><name><surname>Ward</surname><given-names>T</given-names></name><name><surname>Sheppard</surname><given-names>KE</given-names></name><name><surname>Bukczynska</surname><given-names>PE</given-names></name><name><surname>Young</surname><given-names>RJ</given-names></name><name><surname>Boyle</surname><given-names>SE</given-names></name><name><surname>Shackleton</surname><given-names>M</given-names></name><etal/></person-group><article-title>The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma</article-title><source>Sci Signal</source><year>2015</year><volume>8</volume><fpage>ra82</fpage><pub-id pub-id-type="doi">10.1126/scisignal.aab1111</pub-id><?supplied-pmid 26286024?><pub-id pub-id-type="pmid">26286024</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Konieczkowski</surname><given-names>DJ</given-names></name><name><surname>Johannessen</surname><given-names>CM</given-names></name><name><surname>Abudayyeh</surname><given-names>O</given-names></name><name><surname>Kim</surname><given-names>JW</given-names></name><name><surname>Cooper</surname><given-names>ZA</given-names></name><name><surname>Piris</surname><given-names>A</given-names></name><name><surname>Frederick</surname><given-names>DT</given-names></name><name><surname>Barzily-Rokni</surname><given-names>M</given-names></name><name><surname>Straussman</surname><given-names>R</given-names></name><name><surname>Haq</surname><given-names>R</given-names></name><etal/></person-group><article-title>A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors</article-title><source>Cancer Discov</source><year>2014</year><volume>4</volume><fpage>816</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-13-0424</pub-id><?supplied-pmid 24771846?><pub-id pub-id-type="pmid">24771846</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johannessen</surname><given-names>CM</given-names></name><name><surname>Johnson</surname><given-names>LA</given-names></name><name><surname>Piccioni</surname><given-names>F</given-names></name><name><surname>Townes</surname><given-names>A</given-names></name><name><surname>Frederick</surname><given-names>DT</given-names></name><name><surname>Donahue</surname><given-names>MK</given-names></name><name><surname>Narayan</surname><given-names>R</given-names></name><name><surname>Flaherty</surname><given-names>KT</given-names></name><name><surname>Wargo</surname><given-names>JA</given-names></name><name><surname>Root</surname><given-names>DE</given-names></name><name><surname>Garraway</surname><given-names>LA</given-names></name></person-group><article-title>A melanocyte lineage program confers resistance to MAP kinase pathway inhibition</article-title><source>Nature</source><year>2013</year><volume>504</volume><fpage>138</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1038/nature12688</pub-id><?supplied-pmid 24185007?><pub-id pub-id-type="pmid">24185007</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caramel</surname><given-names>J</given-names></name><name><surname>Papadogeorgakis</surname><given-names>E</given-names></name><name><surname>Hill</surname><given-names>L</given-names></name><name><surname>Browne</surname><given-names>GJ</given-names></name><name><surname>Richard</surname><given-names>G</given-names></name><name><surname>Wierinckx</surname><given-names>A</given-names></name><name><surname>Saldanha</surname><given-names>G</given-names></name><name><surname>Osborne</surname><given-names>J</given-names></name><name><surname>Hutchinson</surname><given-names>P</given-names></name><name><surname>Tse</surname><given-names>G</given-names></name><etal/></person-group><article-title>A switch in the expression of embryonic EMT-inducers drives the development of malignant melanoma</article-title><source>Cancer Cell</source><year>2013</year><volume>24</volume><fpage>466</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2013.08.018</pub-id><?supplied-pmid 24075834?><pub-id pub-id-type="pmid">24075834</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alonso</surname><given-names>SR</given-names></name><name><surname>Tracey</surname><given-names>L</given-names></name><name><surname>Ortiz</surname><given-names>P</given-names></name><name><surname>Perez-Gomez</surname><given-names>B</given-names></name><name><surname>Palacios</surname><given-names>J</given-names></name><name><surname>Pollan</surname><given-names>M</given-names></name><name><surname>Linares</surname><given-names>J</given-names></name><name><surname>Serrano</surname><given-names>S</given-names></name><name><surname>Saez-Castillo</surname><given-names>AI</given-names></name><name><surname>Sanchez</surname><given-names>L</given-names></name><etal/></person-group><article-title>A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis</article-title><source>Cancer Res</source><year>2007</year><volume>67</volume><fpage>3450</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-3481</pub-id><?supplied-pmid 17409456?><pub-id pub-id-type="pmid">17409456</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hao</surname><given-names>L</given-names></name><name><surname>Ha</surname><given-names>JR</given-names></name><name><surname>Kuzel</surname><given-names>P</given-names></name><name><surname>Garcia</surname><given-names>E</given-names></name><name><surname>Persad</surname><given-names>S</given-names></name></person-group><article-title>Cadherin switch from E- to N-cadherin in melanoma progression is regulated by the PI3K/PTEN pathway through Twist and Snail</article-title><source>Br J Dermatol</source><year>2012</year><volume>166</volume><fpage>1184</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2133.2012.10824.x</pub-id><?supplied-pmid 22332917?><pub-id pub-id-type="pmid">22332917</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carreira</surname><given-names>S</given-names></name><name><surname>Goodall</surname><given-names>J</given-names></name><name><surname>Denat</surname><given-names>L</given-names></name><name><surname>Rodriguez</surname><given-names>M</given-names></name><name><surname>Nuciforo</surname><given-names>P</given-names></name><name><surname>Hoek</surname><given-names>KS</given-names></name><name><surname>Testori</surname><given-names>A</given-names></name><name><surname>Larue</surname><given-names>L</given-names></name><name><surname>Goding</surname><given-names>CR</given-names></name></person-group><article-title>Mitf regulation of Dia1 controls melanoma proliferation and invasiveness</article-title><source>Genes Dev</source><year>2006</year><volume>20</volume><fpage>3426</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1101/gad.406406</pub-id><?supplied-pmid 17182868?><pub-id pub-id-type="pmid">17182868</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tili</surname><given-names>E</given-names></name><name><surname>Michaille</surname><given-names>JJ</given-names></name><name><surname>Croce</surname><given-names>CM</given-names></name></person-group><article-title>MicroRNAs play a central role in molecular dysfunctions linking inflammation with cancer</article-title><source>Immunol Rev</source><year>2013</year><volume>253</volume><fpage>167</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1111/imr.12050</pub-id><?supplied-pmid 23550646?><pub-id pub-id-type="pmid">23550646</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olive</surname><given-names>V</given-names></name><name><surname>Jiang</surname><given-names>I</given-names></name><name><surname>He</surname><given-names>L</given-names></name></person-group><article-title>mir-17-92, a cluster of miRNAs in the midst of the cancer network</article-title><source>Int J Biochem Cell Biol</source><year>2010</year><volume>42</volume><fpage>1348</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1016/j.biocel.2010.03.004</pub-id><?supplied-pmid 20227518?><pub-id pub-id-type="pmid">20227518</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bracken</surname><given-names>CP</given-names></name><name><surname>Gregory</surname><given-names>PA</given-names></name><name><surname>Kolesnikoff</surname><given-names>N</given-names></name><name><surname>Bert</surname><given-names>AG</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Shannon</surname><given-names>MF</given-names></name><name><surname>Goodall</surname><given-names>GJ</given-names></name></person-group><article-title>A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition</article-title><source>Cancer Res</source><year>2008</year><volume>68</volume><fpage>7846</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-1942</pub-id><?supplied-pmid 18829540?><pub-id pub-id-type="pmid">18829540</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gregory</surname><given-names>PA</given-names></name><name><surname>Bracken</surname><given-names>CP</given-names></name><name><surname>Smith</surname><given-names>E</given-names></name><name><surname>Bert</surname><given-names>AG</given-names></name><name><surname>Wright</surname><given-names>JA</given-names></name><name><surname>Roslan</surname><given-names>S</given-names></name><name><surname>Morris</surname><given-names>M</given-names></name><name><surname>Wyatt</surname><given-names>L</given-names></name><name><surname>Farshid</surname><given-names>G</given-names></name><name><surname>Lim</surname><given-names>YY</given-names></name><etal/></person-group><article-title>An autocrine TGF-beta/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition</article-title><source>Mol Biol Cell</source><year>2011</year><volume>22</volume><fpage>1686</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1091/mbc.E11-02-0103</pub-id><?supplied-pmid 21411626?><pub-id pub-id-type="pmid">21411626</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haflidadottir</surname><given-names>BS</given-names></name><name><surname>Bergsteinsdottir</surname><given-names>K</given-names></name><name><surname>Praetorius</surname><given-names>C</given-names></name><name><surname>Steingrimsson</surname><given-names>E</given-names></name></person-group><article-title>miR-148 regulates Mitf in melanoma cells</article-title><source>PLoS One</source><year>2010</year><volume>5</volume><pub-id pub-id-type="doi">10.1371/journal.pone.0011574</pub-id><?supplied-pmid 20644734?><pub-id pub-id-type="pmid">20644734</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kappelmann</surname><given-names>M</given-names></name><name><surname>Kuphal</surname><given-names>S</given-names></name><name><surname>Meister</surname><given-names>G</given-names></name><name><surname>Vardimon</surname><given-names>L</given-names></name><name><surname>Bosserhoff</surname><given-names>AK</given-names></name></person-group><article-title>MicroRNA miR-125b controls melanoma progression by direct regulation of c-Jun protein expression</article-title><source>Oncogene</source><year>2013</year><volume>32</volume><fpage>2984</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1038/onc.2012.307</pub-id><?supplied-pmid 22797068?><pub-id pub-id-type="pmid">22797068</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Couts</surname><given-names>KL</given-names></name><name><surname>Anderson</surname><given-names>EM</given-names></name><name><surname>Gross</surname><given-names>MM</given-names></name><name><surname>Sullivan</surname><given-names>K</given-names></name><name><surname>Ahn</surname><given-names>NG</given-names></name></person-group><article-title>Oncogenic B-Raf signaling in melanoma cells controls a network of microRNAs with combinatorial functions</article-title><source>Oncogene</source><year>2013</year><volume>32</volume><fpage>1959</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1038/onc.2012.209</pub-id><?supplied-pmid 22751131?><pub-id pub-id-type="pmid">22751131</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Streicher</surname><given-names>KL</given-names></name><name><surname>Zhu</surname><given-names>W</given-names></name><name><surname>Lehmann</surname><given-names>KP</given-names></name><name><surname>Georgantas</surname><given-names>RW</given-names></name><name><surname>Morehouse</surname><given-names>CA</given-names></name><name><surname>Brohawn</surname><given-names>P</given-names></name><name><surname>Carrasco</surname><given-names>RA</given-names></name><name><surname>Xiao</surname><given-names>Z</given-names></name><name><surname>Tice</surname><given-names>DA</given-names></name><name><surname>Higgs</surname><given-names>BW</given-names></name><etal/></person-group><article-title>A novel oncogenic role for the miRNA-506-514 cluster in initiating melanocyte transformation and promoting melanoma growth</article-title><source>Oncogene</source><year>2012</year><volume>31</volume><fpage>1558</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1038/onc.2011.345</pub-id><?supplied-pmid 21860416?><pub-id pub-id-type="pmid">21860416</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schultz</surname><given-names>J</given-names></name><name><surname>Lorenz</surname><given-names>P</given-names></name><name><surname>Gross</surname><given-names>G</given-names></name><name><surname>Ibrahim</surname><given-names>S</given-names></name><name><surname>Kunz</surname><given-names>M</given-names></name></person-group><article-title>MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth</article-title><source>Cell Res</source><year>2008</year><volume>18</volume><fpage>549</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1038/cr.2008.45</pub-id><?supplied-pmid 18379589?><pub-id pub-id-type="pmid">18379589</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Felicetti</surname><given-names>F</given-names></name><name><surname>Errico</surname><given-names>MC</given-names></name><name><surname>Bottero</surname><given-names>L</given-names></name><name><surname>Segnalini</surname><given-names>P</given-names></name><name><surname>Stoppacciaro</surname><given-names>A</given-names></name><name><surname>Biffoni</surname><given-names>M</given-names></name><name><surname>Felli</surname><given-names>N</given-names></name><name><surname>Mattia</surname><given-names>G</given-names></name><name><surname>Petrini</surname><given-names>M</given-names></name><name><surname>Colombo</surname><given-names>MP</given-names></name><etal/></person-group><article-title>The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms</article-title><source>Cancer Res</source><year>2008</year><volume>68</volume><fpage>2745</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-2538</pub-id><?supplied-pmid 18417445?><pub-id pub-id-type="pmid">18417445</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonazzi</surname><given-names>VF</given-names></name><name><surname>Stark</surname><given-names>MS</given-names></name><name><surname>Hayward</surname><given-names>NK</given-names></name></person-group><article-title>MicroRNA regulation of melanoma progression</article-title><source>Melanoma Res</source><year>2012</year><volume>22</volume><fpage>101</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1097/CMR.0b013e32834f6fbb</pub-id><?supplied-pmid 22209751?><pub-id pub-id-type="pmid">22209751</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dar</surname><given-names>AA</given-names></name><name><surname>Majid</surname><given-names>S</given-names></name><name><surname>Rittsteuer</surname><given-names>C</given-names></name><name><surname>de Semir</surname><given-names>D</given-names></name><name><surname>Bezrookove</surname><given-names>V</given-names></name><name><surname>Tong</surname><given-names>S</given-names></name><name><surname>Nosrati</surname><given-names>M</given-names></name><name><surname>Sagebiel</surname><given-names>R</given-names></name><name><surname>Miller</surname><given-names>JR</given-names><suffix>3rd</suffix></name><name><surname>Kashani-Sabet</surname><given-names>M</given-names></name></person-group><article-title>The role of miR-18b in MDM2-p53 pathway signaling and melanoma progression</article-title><source>J Natl Cancer Inst</source><year>2013</year><volume>105</volume><fpage>433</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1093/jnci/djt003</pub-id><?supplied-pmid 23365201?><pub-id pub-id-type="pmid">23365201</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Penna</surname><given-names>E</given-names></name><name><surname>Orso</surname><given-names>F</given-names></name><name><surname>Cimino</surname><given-names>D</given-names></name><name><surname>Vercellino</surname><given-names>I</given-names></name><name><surname>Grassi</surname><given-names>E</given-names></name><name><surname>Quaglino</surname><given-names>E</given-names></name><name><surname>Turco</surname><given-names>E</given-names></name><name><surname>Taverna</surname><given-names>D</given-names></name></person-group><article-title>miR-214 coordinates melanoma progression by upregulating ALCAM through TFAP2 and miR-148b downmodulation</article-title><source>Cancer Res</source><year>2013</year><volume>73</volume><fpage>4098</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-12-3686</pub-id><?supplied-pmid 23667173?><pub-id pub-id-type="pmid">23667173</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bell</surname><given-names>RE</given-names></name><name><surname>Khaled</surname><given-names>M</given-names></name><name><surname>Netanely</surname><given-names>D</given-names></name><name><surname>Schubert</surname><given-names>S</given-names></name><name><surname>Golan</surname><given-names>T</given-names></name><name><surname>Buxbaum</surname><given-names>A</given-names></name><name><surname>Janas</surname><given-names>MM</given-names></name><name><surname>Postolsky</surname><given-names>B</given-names></name><name><surname>Goldberg</surname><given-names>MS</given-names></name><name><surname>Shamir</surname><given-names>R</given-names></name><name><surname>Levy</surname><given-names>C</given-names></name></person-group><article-title>Transcription factor/microRNA axis blocks melanoma invasion program by miR-211 targeting NUAK1</article-title><source>J Invest Dermatol</source><year>2014</year><volume>134</volume><fpage>441</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1038/jid.2013.340</pub-id><?supplied-pmid 23934065?><pub-id pub-id-type="pmid">23934065</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elson-Schwab</surname><given-names>I</given-names></name><name><surname>Lorentzen</surname><given-names>A</given-names></name><name><surname>Marshall</surname><given-names>CJ</given-names></name></person-group><article-title>MicroRNA-200 family members differentially regulate morphological plasticity and mode of melanoma cell invasion</article-title><source>PLoS One</source><year>2010</year><volume>5</volume><issue>10</issue><pub-id pub-id-type="doi">10.1371/journal.pone.0013176</pub-id><?supplied-pmid 20957176?><pub-id pub-id-type="pmid">20957176</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bracken</surname><given-names>CP</given-names></name><name><surname>Khew-Goodall</surname><given-names>Y</given-names></name><name><surname>Goodall</surname><given-names>GJ</given-names></name></person-group><article-title>Network-based approaches to understand the roles of miR-200 and other microRNAs in cancer</article-title><source>Cancer Res</source><year>2015</year><volume>75</volume><fpage>2594</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-15-0287</pub-id><?supplied-pmid 26069247?><pub-id pub-id-type="pmid">26069247</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bracken</surname><given-names>CP</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Wright</surname><given-names>JA</given-names></name><name><surname>Lawrence</surname><given-names>DM</given-names></name><name><surname>Pillman</surname><given-names>KA</given-names></name><name><surname>Salmanidis</surname><given-names>M</given-names></name><name><surname>Anderson</surname><given-names>MA</given-names></name><name><surname>Dredge</surname><given-names>BK</given-names></name><name><surname>Gregory</surname><given-names>PA</given-names></name><name><surname>Tsykin</surname><given-names>A</given-names></name><etal/></person-group><article-title>Genome-wide identification of miR-200 targets reveals a regulatory network controlling cell invasion</article-title><source>EMBO J</source><year>2014</year><volume>33</volume><fpage>2040</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.15252/embj.201488641</pub-id><?supplied-pmid 25069772?><pub-id pub-id-type="pmid">25069772</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Selbach</surname><given-names>M</given-names></name><name><surname>Schwanhausser</surname><given-names>B</given-names></name><name><surname>Thierfelder</surname><given-names>N</given-names></name><name><surname>Fang</surname><given-names>Z</given-names></name><name><surname>Khanin</surname><given-names>R</given-names></name><name><surname>Rajewsky</surname><given-names>N</given-names></name></person-group><article-title>Widespread changes in protein synthesis induced by microRNAs</article-title><source>Nature</source><year>2008</year><volume>455</volume><fpage>58</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1038/nature07228</pub-id><?supplied-pmid 18668040?><pub-id pub-id-type="pmid">18668040</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>Ingolia</surname><given-names>NT</given-names></name><name><surname>Weissman</surname><given-names>JS</given-names></name><name><surname>Bartel</surname><given-names>DP</given-names></name></person-group><article-title>Mammalian microRNAs predominantly act to decrease target mRNA levels</article-title><source>Nature</source><year>2010</year><volume>466</volume><fpage>835</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1038/nature09267</pub-id><?supplied-pmid 20703300?><pub-id pub-id-type="pmid">20703300</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eichhorn</surname><given-names>SW</given-names></name><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>McGeary</surname><given-names>SE</given-names></name><name><surname>Rodriguez-Mias</surname><given-names>RA</given-names></name><name><surname>Shin</surname><given-names>C</given-names></name><name><surname>Baek</surname><given-names>D</given-names></name><name><surname>Hsu</surname><given-names>SH</given-names></name><name><surname>Ghoshal</surname><given-names>K</given-names></name><name><surname>Villen</surname><given-names>J</given-names></name><name><surname>Bartel</surname><given-names>DP</given-names></name></person-group><article-title>mRNA destabilization is the dominant effect of mammalian microRNAs by the time substantial repression ensues</article-title><source>Mol Cell</source><year>2014</year><volume>56</volume><fpage>104</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2014.08.028</pub-id><?supplied-pmid 25263593?><pub-id pub-id-type="pmid">25263593</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baek</surname><given-names>D</given-names></name><name><surname>Villen</surname><given-names>J</given-names></name><name><surname>Shin</surname><given-names>C</given-names></name><name><surname>Camargo</surname><given-names>FD</given-names></name><name><surname>Gygi</surname><given-names>SP</given-names></name><name><surname>Bartel</surname><given-names>DP</given-names></name></person-group><article-title>The impact of microRNAs on protein output</article-title><source>Nature</source><year>2008</year><volume>455</volume><fpage>64</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1038/nature07242</pub-id><?supplied-pmid 18668037?><pub-id pub-id-type="pmid">18668037</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jonas</surname><given-names>S</given-names></name><name><surname>Izaurralde</surname><given-names>E</given-names></name></person-group><article-title>Towards a molecular understanding of microRNA-mediated gene silencing</article-title><source>Nat Rev Genet</source><year>2015</year><volume>16</volume><fpage>421</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1038/nrg3965</pub-id><?supplied-pmid 26077373?><pub-id pub-id-type="pmid">26077373</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cloonan</surname><given-names>N</given-names></name></person-group><article-title>Re-thinking miRNA-mRNA interactions: intertwining issues confound target discovery</article-title><source>Bioessays</source><year>2015</year><volume>37</volume><fpage>379</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1002/bies.201400191</pub-id><?supplied-pmid 25683051?><pub-id pub-id-type="pmid">25683051</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Plaisier</surname><given-names>CL</given-names></name><name><surname>Pan</surname><given-names>M</given-names></name><name><surname>Baliga</surname><given-names>NS</given-names></name></person-group><article-title>A miRNA-regulatory network explains how dysregulated miRNAs perturb oncogenic processes across diverse cancers</article-title><source>Genome Res</source><year>2012</year><volume>22</volume><fpage>2302</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1101/gr.133991.111</pub-id><?supplied-pmid 22745231?><pub-id pub-id-type="pmid">22745231</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Denzler</surname><given-names>R</given-names></name><name><surname>Agarwal</surname><given-names>V</given-names></name><name><surname>Stefano</surname><given-names>J</given-names></name><name><surname>Bartel</surname><given-names>DP</given-names></name><name><surname>Stoffel</surname><given-names>M</given-names></name></person-group><article-title>Assessing the ceRNA hypothesis with quantitative measurements of miRNA and target abundance</article-title><source>Mol Cell</source><year>2014</year><volume>54</volume><fpage>766</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2014.03.045</pub-id><?supplied-pmid 24793693?><pub-id pub-id-type="pmid">24793693</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanchez-Mejias</surname><given-names>A</given-names></name><name><surname>Tay</surname><given-names>Y</given-names></name></person-group><article-title>Competing endogenous RNA networks: tying the essential knots for cancer biology and therapeutics</article-title><source>J Hematol Oncol</source><year>2015</year><volume>8</volume><fpage>30</fpage><pub-id pub-id-type="doi">10.1186/s13045-015-0129-1</pub-id><?supplied-pmid 25888444?><pub-id pub-id-type="pmid">25888444</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Memczak</surname><given-names>S</given-names></name><name><surname>Jens</surname><given-names>M</given-names></name><name><surname>Elefsinioti</surname><given-names>A</given-names></name><name><surname>Torti</surname><given-names>F</given-names></name><name><surname>Krueger</surname><given-names>J</given-names></name><name><surname>Rybak</surname><given-names>A</given-names></name><name><surname>Maier</surname><given-names>L</given-names></name><name><surname>Mackowiak</surname><given-names>SD</given-names></name><name><surname>Gregersen</surname><given-names>LH</given-names></name><name><surname>Munschauer</surname><given-names>M</given-names></name><etal/></person-group><article-title>Circular RNAs are a large class of animal RNAs with regulatory potency</article-title><source>Nature</source><year>2013</year><volume>495</volume><fpage>333</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1038/nature11928</pub-id><?supplied-pmid 23446348?><pub-id pub-id-type="pmid">23446348</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conn</surname><given-names>SJ</given-names></name><name><surname>Pillman</surname><given-names>KA</given-names></name><name><surname>Toubia</surname><given-names>J</given-names></name><name><surname>Conn</surname><given-names>VM</given-names></name><name><surname>Salmanidis</surname><given-names>M</given-names></name><name><surname>Phillips</surname><given-names>CA</given-names></name><name><surname>Roslan</surname><given-names>S</given-names></name><name><surname>Schreiber</surname><given-names>AW</given-names></name><name><surname>Gregory</surname><given-names>PA</given-names></name><name><surname>Goodall</surname><given-names>GJ</given-names></name></person-group><article-title>The RNA binding protein quaking regulates formation of circRNAs</article-title><source>Cell</source><year>2015</year><volume>160</volume><fpage>1125</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.02.014</pub-id><?supplied-pmid 25768908?><pub-id pub-id-type="pmid">25768908</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Philippidou</surname><given-names>D</given-names></name><name><surname>Schmitt</surname><given-names>M</given-names></name><name><surname>Moser</surname><given-names>D</given-names></name><name><surname>Margue</surname><given-names>C</given-names></name><name><surname>Nazarov</surname><given-names>PV</given-names></name><name><surname>Muller</surname><given-names>A</given-names></name><name><surname>Vallar</surname><given-names>L</given-names></name><name><surname>Nashan</surname><given-names>D</given-names></name><name><surname>Behrmann</surname><given-names>I</given-names></name><name><surname>Kreis</surname><given-names>S</given-names></name></person-group><article-title>Signatures of microRNAs and selected microRNA target genes in human melanoma</article-title><source>Cancer Res</source><year>2010</year><volume>70</volume><fpage>4163</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-4512</pub-id><?supplied-pmid 20442294?><pub-id pub-id-type="pmid">20442294</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Behren</surname><given-names>A</given-names></name><name><surname>Anaka</surname><given-names>M</given-names></name><name><surname>Lo</surname><given-names>PH</given-names></name><name><surname>Vella</surname><given-names>LJ</given-names></name><name><surname>Davis</surname><given-names>ID</given-names></name><name><surname>Catimel</surname><given-names>J</given-names></name><name><surname>Cardwell</surname><given-names>T</given-names></name><name><surname>Gedye</surname><given-names>C</given-names></name><name><surname>Hudson</surname><given-names>C</given-names></name><name><surname>Stan</surname><given-names>R</given-names></name><name><surname>Cebon</surname><given-names>J</given-names></name></person-group><article-title>The Ludwig institute for cancer research Melbourne melanoma cell line panel</article-title><source>Pigment Cell Melanoma Res</source><year>2013</year><volume>26</volume><fpage>597</fpage><lpage>600</lpage><pub-id pub-id-type="doi">10.1111/pcmr.12097</pub-id><?supplied-pmid 23527996?><pub-id pub-id-type="pmid">23527996</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jayachandran</surname><given-names>A</given-names></name><name><surname>Anaka</surname><given-names>M</given-names></name><name><surname>Prithviraj</surname><given-names>P</given-names></name><name><surname>Hudson</surname><given-names>C</given-names></name><name><surname>McKeown</surname><given-names>SJ</given-names></name><name><surname>Lo</surname><given-names>PH</given-names></name><name><surname>Vella</surname><given-names>LJ</given-names></name><name><surname>Goding</surname><given-names>CR</given-names></name><name><surname>Cebon</surname><given-names>J</given-names></name><name><surname>Behren</surname><given-names>A</given-names></name></person-group><article-title>Thrombospondin 1 promotes an aggressive phenotype through epithelial-to-mesenchymal transition in human melanoma</article-title><source>Oncotarget</source><year>2014</year><volume>5</volume><fpage>5782</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.2164</pub-id><?supplied-pmid 25051363?><pub-id pub-id-type="pmid">25051363</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hurley</surname><given-names>DG</given-names></name><name><surname>Cursons</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>YK</given-names></name><name><surname>Budden</surname><given-names>DM</given-names></name><name><surname>Print</surname><given-names>CG</given-names></name><name><surname>Crampin</surname><given-names>EJ</given-names></name></person-group><article-title>NAIL, a software toolset for inferring, analyzing and visualizing regulatory networks</article-title><source>Bioinformatics</source><year>2015</year><volume>31</volume><fpage>277</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btu612</pub-id><?supplied-pmid 25246431?><pub-id pub-id-type="pmid">25246431</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><mixed-citation publication-type="other">Lizier JT. JIDT: An information-theoretic toolkit for studying the dynamics of complex systems. arXiv preprint arXiv:14083270 2014.</mixed-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reshef</surname><given-names>DN</given-names></name><name><surname>Reshef</surname><given-names>YA</given-names></name><name><surname>Finucane</surname><given-names>HK</given-names></name><name><surname>Grossman</surname><given-names>SR</given-names></name><name><surname>McVean</surname><given-names>G</given-names></name><name><surname>Turnbaugh</surname><given-names>PJ</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Mitzenmacher</surname><given-names>M</given-names></name><name><surname>Sabeti</surname><given-names>PC</given-names></name></person-group><article-title>Detecting novel associations in large data sets</article-title><source>Science</source><year>2011</year><volume>334</volume><fpage>1518</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1126/science.1205438</pub-id><?supplied-pmid 22174245?><pub-id pub-id-type="pmid">22174245</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Basso</surname><given-names>K</given-names></name><name><surname>Margolin</surname><given-names>AA</given-names></name><name><surname>Stolovitzky</surname><given-names>G</given-names></name><name><surname>Klein</surname><given-names>U</given-names></name><name><surname>Dalla-Favera</surname><given-names>R</given-names></name><name><surname>Califano</surname><given-names>A</given-names></name></person-group><article-title>Reverse engineering of regulatory networks in human B cells</article-title><source>Nat Genet</source><year>2005</year><volume>37</volume><fpage>382</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1038/ng1532</pub-id><?supplied-pmid 15778709?><pub-id pub-id-type="pmid">15778709</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Budden</surname><given-names>DM</given-names></name><name><surname>Crampin</surname><given-names>EJ</given-names></name></person-group><article-title>Information theoretic approaches for inference of biological networks from continuous-valued data</article-title><source>BMC Syst Biol</source><year>2016</year><volume>10</volume><fpage>89</fpage><pub-id pub-id-type="doi">10.1186/s12918-016-0331-y</pub-id><?supplied-pmid 27599566?><pub-id pub-id-type="pmid">27599566</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>RC</given-names></name><name><surname>Farh</surname><given-names>KK</given-names></name><name><surname>Burge</surname><given-names>CB</given-names></name><name><surname>Bartel</surname><given-names>DP</given-names></name></person-group><article-title>Most mammalian mRNAs are conserved targets of microRNAs</article-title><source>Genome Res</source><year>2009</year><volume>19</volume><fpage>92</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1101/gr.082701.108</pub-id><?supplied-pmid 18955434?><pub-id pub-id-type="pmid">18955434</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grimson</surname><given-names>A</given-names></name><name><surname>Farh</surname><given-names>KK</given-names></name><name><surname>Johnston</surname><given-names>WK</given-names></name><name><surname>Garrett-Engele</surname><given-names>P</given-names></name><name><surname>Lim</surname><given-names>LP</given-names></name><name><surname>Bartel</surname><given-names>DP</given-names></name></person-group><article-title>MicroRNA targeting specificity in mammals: determinants beyond seed pairing</article-title><source>Mol Cell</source><year>2007</year><volume>27</volume><fpage>91</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2007.06.017</pub-id><?supplied-pmid 17612493?><pub-id pub-id-type="pmid">17612493</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>BP</given-names></name><name><surname>Burge</surname><given-names>CB</given-names></name><name><surname>Bartel</surname><given-names>DP</given-names></name></person-group><article-title>Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets</article-title><source>Cell</source><year>2005</year><volume>120</volume><fpage>15</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2004.12.035</pub-id><?supplied-pmid 15652477?><pub-id pub-id-type="pmid">15652477</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paraskevopoulou</surname><given-names>MD</given-names></name><name><surname>Georgakilas</surname><given-names>G</given-names></name><name><surname>Kostoulas</surname><given-names>N</given-names></name><name><surname>Vlachos</surname><given-names>IS</given-names></name><name><surname>Vergoulis</surname><given-names>T</given-names></name><name><surname>Reczko</surname><given-names>M</given-names></name><name><surname>Filippidis</surname><given-names>C</given-names></name><name><surname>Dalamagas</surname><given-names>T</given-names></name><name><surname>Hatzigeorgiou</surname><given-names>AG</given-names></name></person-group><article-title>DIANA-microT web server v5.0: service integration into miRNA functional analysis workflows</article-title><source>Nucleic Acids Res</source><year>2013</year><volume>41</volume><fpage>W169</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1093/nar/gkt393</pub-id><?supplied-pmid 23680784?><pub-id pub-id-type="pmid">23680784</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reczko</surname><given-names>M</given-names></name><name><surname>Maragkakis</surname><given-names>M</given-names></name><name><surname>Alexiou</surname><given-names>P</given-names></name><name><surname>Grosse</surname><given-names>I</given-names></name><name><surname>Hatzigeorgiou</surname><given-names>AG</given-names></name></person-group><article-title>Functional microRNA targets in protein coding sequences</article-title><source>Bioinformatics</source><year>2012</year><volume>28</volume><fpage>771</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bts043</pub-id><?supplied-pmid 22285563?><pub-id pub-id-type="pmid">22285563</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Cancer Genome Atlas Research N</collab><name><surname>Weinstein</surname><given-names>JN</given-names></name><name><surname>Collisson</surname><given-names>EA</given-names></name><name><surname>Mills</surname><given-names>GB</given-names></name><name><surname>Shaw</surname><given-names>KR</given-names></name><name><surname>Ozenberger</surname><given-names>BA</given-names></name><name><surname>Ellrott</surname><given-names>K</given-names></name><name><surname>Shmulevich</surname><given-names>I</given-names></name><name><surname>Sander</surname><given-names>C</given-names></name><name><surname>Stuart</surname><given-names>JM</given-names></name></person-group><article-title>The Cancer Genome Atlas Pan-Cancer analysis project</article-title><source>Nat Genet</source><year>2013</year><volume>45</volume><fpage>1113</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1038/ng.2764</pub-id><pub-id pub-id-type="pmid">24071849</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levy</surname><given-names>C</given-names></name><name><surname>Khaled</surname><given-names>M</given-names></name><name><surname>Fisher</surname><given-names>DE</given-names></name></person-group><article-title>MITF: master regulator of melanocyte development and melanoma oncogene</article-title><source>Trends Mol Med</source><year>2006</year><volume>12</volume><fpage>406</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/j.molmed.2006.07.008</pub-id><?supplied-pmid 16899407?><pub-id pub-id-type="pmid">16899407</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fufa</surname><given-names>TD</given-names></name><name><surname>Harris</surname><given-names>ML</given-names></name><name><surname>Watkins-Chow</surname><given-names>DE</given-names></name><name><surname>Levy</surname><given-names>D</given-names></name><name><surname>Gorkin</surname><given-names>DU</given-names></name><name><surname>Gildea</surname><given-names>DE</given-names></name><name><surname>Song</surname><given-names>L</given-names></name><name><surname>Safi</surname><given-names>A</given-names></name><name><surname>Crawford</surname><given-names>GE</given-names></name><name><surname>Sviderskaya</surname><given-names>EV</given-names></name><etal/></person-group><article-title>Genomic analysis reveals distinct mechanisms and functional classes of SOX10-regulated genes in melanocytes</article-title><source>Hum Mol Genet</source><year>2015</year><volume>24</volume><fpage>5433</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddv267</pub-id><?supplied-pmid 26206884?><pub-id pub-id-type="pmid">26206884</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>PF</given-names></name><name><surname>Shakhova</surname><given-names>O</given-names></name><name><surname>Widmer</surname><given-names>DS</given-names></name><name><surname>Eichhoff</surname><given-names>OM</given-names></name><name><surname>Zingg</surname><given-names>D</given-names></name><name><surname>Frommel</surname><given-names>SC</given-names></name><name><surname>Belloni</surname><given-names>B</given-names></name><name><surname>Raaijmakers</surname><given-names>MI</given-names></name><name><surname>Goldinger</surname><given-names>SM</given-names></name><name><surname>Santoro</surname><given-names>R</given-names></name><etal/></person-group><article-title>Methylation-dependent SOX9 expression mediates invasion in human melanoma cells and is a negative prognostic factor in advanced melanoma</article-title><source>Genome Biol</source><year>2015</year><volume>16</volume><fpage>42</fpage><pub-id pub-id-type="doi">10.1186/s13059-015-0594-4</pub-id><?supplied-pmid 25885555?><pub-id pub-id-type="pmid">25885555</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shakhova</surname><given-names>O</given-names></name><name><surname>Cheng</surname><given-names>P</given-names></name><name><surname>Mishra</surname><given-names>PJ</given-names></name><name><surname>Zingg</surname><given-names>D</given-names></name><name><surname>Schaefer</surname><given-names>SM</given-names></name><name><surname>Debbache</surname><given-names>J</given-names></name><name><surname>Hausel</surname><given-names>J</given-names></name><name><surname>Matter</surname><given-names>C</given-names></name><name><surname>Guo</surname><given-names>T</given-names></name><name><surname>Davis</surname><given-names>S</given-names></name><etal/></person-group><article-title>Antagonistic cross-regulation between Sox9 and Sox10 controls an anti-tumorigenic program in melanoma</article-title><source>PLoS Genet</source><year>2015</year><volume>11</volume><pub-id pub-id-type="doi">10.1371/journal.pgen.1004877</pub-id><?supplied-pmid 25629959?><pub-id pub-id-type="pmid">25629959</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Heynen</surname><given-names>GJ</given-names></name><name><surname>Prahallad</surname><given-names>A</given-names></name><name><surname>Robert</surname><given-names>C</given-names></name><name><surname>Haanen</surname><given-names>J</given-names></name><name><surname>Blank</surname><given-names>C</given-names></name><name><surname>Wesseling</surname><given-names>J</given-names></name><name><surname>Willems</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma</article-title><source>Nature</source><year>2014</year><volume>508</volume><fpage>118</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1038/nature13121</pub-id><?supplied-pmid 24670642?><pub-id pub-id-type="pmid">24670642</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cursons</surname><given-names>J</given-names></name><name><surname>Leuchowius</surname><given-names>KJ</given-names></name><name><surname>Waltham</surname><given-names>M</given-names></name><name><surname>Tomaskovic-Crook</surname><given-names>E</given-names></name><name><surname>Foroutan</surname><given-names>M</given-names></name><name><surname>Bracken</surname><given-names>CP</given-names></name><name><surname>Redfern</surname><given-names>A</given-names></name><name><surname>Crampin</surname><given-names>EJ</given-names></name><name><surname>Street</surname><given-names>I</given-names></name><name><surname>Davis</surname><given-names>MJ</given-names></name><name><surname>Thompson</surname><given-names>EW</given-names></name></person-group><article-title>Stimulus-dependent differences in signalling regulate epithelial-mesenchymal plasticity and change the effects of drugs in breast cancer cell lines</article-title><source>Cell Commun Signal</source><year>2015</year><volume>13</volume><fpage>26</fpage><pub-id pub-id-type="doi">10.1186/s12964-015-0106-x</pub-id><?supplied-pmid 25975820?><pub-id pub-id-type="pmid">25975820</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levy</surname><given-names>C</given-names></name><name><surname>Khaled</surname><given-names>M</given-names></name><name><surname>Iliopoulos</surname><given-names>D</given-names></name><name><surname>Janas</surname><given-names>MM</given-names></name><name><surname>Schubert</surname><given-names>S</given-names></name><name><surname>Pinner</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>PH</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Fletcher</surname><given-names>AL</given-names></name><name><surname>Yokoyama</surname><given-names>S</given-names></name><etal/></person-group><article-title>Intronic miR-211 assumes the tumor suppressive function of its host gene in melanoma</article-title><source>Mol Cell</source><year>2010</year><volume>40</volume><fpage>841</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2010.11.020</pub-id><?supplied-pmid 21109473?><pub-id pub-id-type="pmid">21109473</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jukic</surname><given-names>DM</given-names></name><name><surname>Rao</surname><given-names>UN</given-names></name><name><surname>Kelly</surname><given-names>L</given-names></name><name><surname>Skaf</surname><given-names>JS</given-names></name><name><surname>Drogowski</surname><given-names>LM</given-names></name><name><surname>Kirkwood</surname><given-names>JM</given-names></name><name><surname>Panelli</surname><given-names>MC</given-names></name></person-group><article-title>Microrna profiling analysis of differences between the melanoma of young adults and older adults</article-title><source>J Transl Med</source><year>2010</year><volume>8</volume><fpage>27</fpage><pub-id pub-id-type="doi">10.1186/1479-5876-8-27</pub-id><?supplied-pmid 20302635?><pub-id pub-id-type="pmid">20302635</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mueller</surname><given-names>DW</given-names></name><name><surname>Rehli</surname><given-names>M</given-names></name><name><surname>Bosserhoff</surname><given-names>AK</given-names></name></person-group><article-title>miRNA expression profiling in melanocytes and melanoma cell lines reveals miRNAs associated with formation and progression of malignant melanoma</article-title><source>J Invest Dermatol</source><year>2009</year><volume>129</volume><fpage>1740</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1038/jid.2008.452</pub-id><?supplied-pmid 19212343?><pub-id pub-id-type="pmid">19212343</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wozniak</surname><given-names>M</given-names></name><name><surname>Sztiller-Sikorska</surname><given-names>M</given-names></name><name><surname>Czyz</surname><given-names>M</given-names></name></person-group><article-title>Diminution of miR-340-5p levels is responsible for increased expression of ABCB5 in melanoma cells under oxygen-deprived conditions</article-title><source>Exp Mol Pathol</source><year>2015</year><volume>99</volume><fpage>707</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/j.yexmp.2015.11.014</pub-id><?supplied-pmid 26554847?><pub-id pub-id-type="pmid">26554847</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poenitzsch Strong</surname><given-names>AM</given-names></name><name><surname>Setaluri</surname><given-names>V</given-names></name><name><surname>Spiegelman</surname><given-names>VS</given-names></name></person-group><article-title>MicroRNA-340 as a modulator of RAS-RAF-MAPK signaling in melanoma</article-title><source>Arch Biochem Biophys</source><year>2014</year><volume>563</volume><fpage>118</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1016/j.abb.2014.07.012</pub-id><?supplied-pmid 25043973?><pub-id pub-id-type="pmid">25043973</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goswami</surname><given-names>S</given-names></name><name><surname>Tarapore</surname><given-names>RS</given-names></name><name><surname>Poenitzsch Strong</surname><given-names>AM</given-names></name><name><surname>TeSlaa</surname><given-names>JJ</given-names></name><name><surname>Grinblat</surname><given-names>Y</given-names></name><name><surname>Setaluri</surname><given-names>V</given-names></name><name><surname>Spiegelman</surname><given-names>VS</given-names></name></person-group><article-title>MicroRNA-340-mediated degradation of microphthalmia-associated transcription factor (MITF) mRNA is inhibited by coding region determinant-binding protein (CRD-BP)</article-title><source>J Biol Chem</source><year>2015</year><volume>290</volume><fpage>384</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1074/jbc.M114.590158</pub-id><?supplied-pmid 25414259?><pub-id pub-id-type="pmid">25414259</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Felicetti</surname><given-names>F</given-names></name><name><surname>Errico</surname><given-names>MC</given-names></name><name><surname>Segnalini</surname><given-names>P</given-names></name><name><surname>Mattia</surname><given-names>G</given-names></name><name><surname>Care</surname><given-names>A</given-names></name></person-group><article-title>MicroRNA-221 and &#x02212;222 pathway controls melanoma progression</article-title><source>Expert Rev Anticancer Ther</source><year>2008</year><volume>8</volume><fpage>1759</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1586/14737140.8.11.1759</pub-id><?supplied-pmid 18983236?><pub-id pub-id-type="pmid">18983236</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanemaru</surname><given-names>H</given-names></name><name><surname>Fukushima</surname><given-names>S</given-names></name><name><surname>Yamashita</surname><given-names>J</given-names></name><name><surname>Honda</surname><given-names>N</given-names></name><name><surname>Oyama</surname><given-names>R</given-names></name><name><surname>Kakimoto</surname><given-names>A</given-names></name><name><surname>Masuguchi</surname><given-names>S</given-names></name><name><surname>Ishihara</surname><given-names>T</given-names></name><name><surname>Inoue</surname><given-names>Y</given-names></name><name><surname>Jinnin</surname><given-names>M</given-names></name><name><surname>Ihn</surname><given-names>H</given-names></name></person-group><article-title>The circulating microRNA-221 level in patients with malignant melanoma as a new tumor marker</article-title><source>J Dermatol Sci</source><year>2011</year><volume>61</volume><fpage>187</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1016/j.jdermsci.2010.12.010</pub-id><?supplied-pmid 21273047?><pub-id pub-id-type="pmid">21273047</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>JX</given-names></name><name><surname>Mai</surname><given-names>SJ</given-names></name><name><surname>Huang</surname><given-names>XX</given-names></name><name><surname>Wang</surname><given-names>FW</given-names></name><name><surname>Liao</surname><given-names>YJ</given-names></name><name><surname>Lin</surname><given-names>MC</given-names></name><name><surname>Kung</surname><given-names>HF</given-names></name><name><surname>Zeng</surname><given-names>YX</given-names></name><name><surname>Xie</surname><given-names>D</given-names></name></person-group><article-title>MiR-29c mediates epithelial-to-mesenchymal transition in human colorectal carcinoma metastasis via PTP4A and GNA13 regulation of beta-catenin signaling</article-title><source>Ann Oncol</source><year>2014</year><volume>25</volume><fpage>2196</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdu439</pub-id><?supplied-pmid 25193986?><pub-id pub-id-type="pmid">25193986</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chou</surname><given-names>J</given-names></name><name><surname>Lin</surname><given-names>JH</given-names></name><name><surname>Brenot</surname><given-names>A</given-names></name><name><surname>Kim</surname><given-names>JW</given-names></name><name><surname>Provot</surname><given-names>S</given-names></name><name><surname>Werb</surname><given-names>Z</given-names></name></person-group><article-title>GATA3 suppresses metastasis and modulates the tumour microenvironment by regulating microRNA-29b expression</article-title><source>Nat Cell Biol</source><year>2013</year><volume>15</volume><fpage>201</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1038/ncb2672</pub-id><?supplied-pmid 23354167?><pub-id pub-id-type="pmid">23354167</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Liao</surname><given-names>Q</given-names></name><name><surname>Cui</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name></person-group><article-title>miR-29b suppresses tumor growth and metastasis in colorectal cancer via downregulating Tiam1 expression and inhibiting epithelial-mesenchymal transition</article-title><source>Cell Death Dis</source><year>2014</year><volume>5</volume><pub-id pub-id-type="doi">10.1038/cddis.2014.304</pub-id><?supplied-pmid 25032858?><pub-id pub-id-type="pmid">25032858</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishikawa</surname><given-names>R</given-names></name><name><surname>Goto</surname><given-names>Y</given-names></name><name><surname>Kojima</surname><given-names>S</given-names></name><name><surname>Enokida</surname><given-names>H</given-names></name><name><surname>Chiyomaru</surname><given-names>T</given-names></name><name><surname>Kinoshita</surname><given-names>T</given-names></name><name><surname>Sakamoto</surname><given-names>S</given-names></name><name><surname>Fuse</surname><given-names>M</given-names></name><name><surname>Nakagawa</surname><given-names>M</given-names></name><name><surname>Naya</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Tumor-suppressive microRNA-29&#x000a0;s inhibit cancer cell migration and invasion via targeting LAMC1 in prostate cancer</article-title><source>Int J Oncol</source><year>2014</year><volume>45</volume><fpage>401</fpage><lpage>10</lpage><?supplied-pmid 24820027?><pub-id pub-id-type="pmid">24820027</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Jia</surname><given-names>H</given-names></name><name><surname>Jiang</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Luo</surname><given-names>M</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Dong</surname><given-names>L</given-names></name><etal/></person-group><article-title>Characterization of microRNA-29 family expression and investigation of their mechanistic roles in gastric cancer</article-title><source>Carcinogenesis</source><year>2014</year><volume>35</volume><fpage>497</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgt337</pub-id><?supplied-pmid 24130168?><pub-id pub-id-type="pmid">24130168</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>N</given-names></name><name><surname>Kinoshita</surname><given-names>T</given-names></name><name><surname>Nohata</surname><given-names>N</given-names></name><name><surname>Yoshino</surname><given-names>H</given-names></name><name><surname>Itesako</surname><given-names>T</given-names></name><name><surname>Fujimura</surname><given-names>L</given-names></name><name><surname>Mitsuhashi</surname><given-names>A</given-names></name><name><surname>Usui</surname><given-names>H</given-names></name><name><surname>Enokida</surname><given-names>H</given-names></name><name><surname>Nakagawa</surname><given-names>M</given-names></name><etal/></person-group><article-title>Tumor-suppressive microRNA-29a inhibits cancer cell migration and invasion via targeting HSP47 in cervical squamous cell carcinoma</article-title><source>Int J Oncol</source><year>2013</year><volume>43</volume><fpage>1855</fpage><lpage>63</lpage><?supplied-pmid 24141696?><pub-id pub-id-type="pmid">24141696</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>T</given-names></name><name><surname>Kuo</surname><given-names>C</given-names></name><name><surname>Nicholl</surname><given-names>MB</given-names></name><name><surname>Sim</surname><given-names>MS</given-names></name><name><surname>Turner</surname><given-names>RR</given-names></name><name><surname>Morton</surname><given-names>DL</given-names></name><name><surname>Hoon</surname><given-names>DS</given-names></name></person-group><article-title>Downregulation of microRNA-29c is associated with hypermethylation of tumor-related genes and disease outcome in cutaneous melanoma</article-title><source>Epigenetics</source><year>2011</year><volume>6</volume><fpage>388</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.4161/epi.6.3.14056</pub-id><?supplied-pmid 21081840?><pub-id pub-id-type="pmid">21081840</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><mixed-citation publication-type="other">Seip K, Fleten KG, Barkovskaya A, Nygaard V, Haugen MH, Engesaeter BO, Maelandsmo GM, Prasmickaite L. Fibroblast-induced switching to the mesenchymal-like phenotype and PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors. Oncotarget. 2016;7(15):19997&#x02013;20015.</mixed-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoek</surname><given-names>KS</given-names></name><name><surname>Goding</surname><given-names>CR</given-names></name></person-group><article-title>Cancer stem cells versus phenotype-switching in melanoma</article-title><source>Pigment Cell Melanoma Res</source><year>2010</year><volume>23</volume><fpage>746</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1111/j.1755-148X.2010.00757.x</pub-id><?supplied-pmid 20726948?><pub-id pub-id-type="pmid">20726948</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinner</surname><given-names>S</given-names></name><name><surname>Jordan</surname><given-names>P</given-names></name><name><surname>Sharrock</surname><given-names>K</given-names></name><name><surname>Bazley</surname><given-names>L</given-names></name><name><surname>Collinson</surname><given-names>L</given-names></name><name><surname>Marais</surname><given-names>R</given-names></name><name><surname>Bonvin</surname><given-names>E</given-names></name><name><surname>Goding</surname><given-names>C</given-names></name><name><surname>Sahai</surname><given-names>E</given-names></name></person-group><article-title>Intravital imaging reveals transient changes in pigment production and Brn2 expression during metastatic melanoma dissemination</article-title><source>Cancer Res</source><year>2009</year><volume>69</volume><fpage>7969</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-0781</pub-id><?supplied-pmid 19826052?><pub-id pub-id-type="pmid">19826052</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flavin</surname><given-names>R</given-names></name><name><surname>Smyth</surname><given-names>P</given-names></name><name><surname>Barrett</surname><given-names>C</given-names></name><name><surname>Russell</surname><given-names>S</given-names></name><name><surname>Wen</surname><given-names>H</given-names></name><name><surname>Wei</surname><given-names>J</given-names></name><name><surname>Laios</surname><given-names>A</given-names></name><name><surname>O'Toole</surname><given-names>S</given-names></name><name><surname>Ring</surname><given-names>M</given-names></name><name><surname>Denning</surname><given-names>K</given-names></name><etal/></person-group><article-title>miR-29b expression is associated with disease-free survival in patients with ovarian serous carcinoma</article-title><source>Int J Gynecol Cancer</source><year>2009</year><volume>19</volume><fpage>641</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1111/IGC.0b013e3181a48cf9</pub-id><?supplied-pmid 19509563?><pub-id pub-id-type="pmid">19509563</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ru</surname><given-names>P</given-names></name><name><surname>Steele</surname><given-names>R</given-names></name><name><surname>Newhall</surname><given-names>P</given-names></name><name><surname>Phillips</surname><given-names>NJ</given-names></name><name><surname>Toth</surname><given-names>K</given-names></name><name><surname>Ray</surname><given-names>RB</given-names></name></person-group><article-title>miRNA-29b suppresses prostate cancer metastasis by regulating epithelial-mesenchymal transition signaling</article-title><source>Mol Cancer Ther</source><year>2012</year><volume>11</volume><fpage>1166</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-12-0100</pub-id><?supplied-pmid 22402125?><pub-id pub-id-type="pmid">22402125</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melo</surname><given-names>SA</given-names></name><name><surname>Kalluri</surname><given-names>R</given-names></name></person-group><article-title>miR-29b moulds the tumour microenvironment to repress metastasis</article-title><source>Nat Cell Biol</source><year>2013</year><volume>15</volume><fpage>139</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1038/ncb2684</pub-id><?supplied-pmid 23377028?><pub-id pub-id-type="pmid">23377028</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmitt</surname><given-names>MJ</given-names></name><name><surname>Philippidou</surname><given-names>D</given-names></name><name><surname>Reinsbach</surname><given-names>SE</given-names></name><name><surname>Margue</surname><given-names>C</given-names></name><name><surname>Wienecke-Baldacchino</surname><given-names>A</given-names></name><name><surname>Nashan</surname><given-names>D</given-names></name><name><surname>Behrmann</surname><given-names>I</given-names></name><name><surname>Kreis</surname><given-names>S</given-names></name></person-group><article-title>Interferon-gamma-induced activation of Signal Transducer and Activator of Transcription 1 (STAT1) up-regulates the tumor suppressing microRNA-29 family in melanoma cells</article-title><source>Cell Commun Signal</source><year>2012</year><volume>10</volume><fpage>41</fpage><pub-id pub-id-type="doi">10.1186/1478-811X-10-41</pub-id><?supplied-pmid 23245396?><pub-id pub-id-type="pmid">23245396</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stocki</surname><given-names>P</given-names></name><name><surname>Chapman</surname><given-names>DC</given-names></name><name><surname>Beach</surname><given-names>LA</given-names></name><name><surname>Williams</surname><given-names>DB</given-names></name></person-group><article-title>Depletion of cyclophilins B and C leads to dysregulation of endoplasmic reticulum redox homeostasis</article-title><source>J Biol Chem</source><year>2014</year><volume>289</volume><fpage>23086</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1074/jbc.M114.570911</pub-id><?supplied-pmid 24990953?><pub-id pub-id-type="pmid">24990953</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khanal</surname><given-names>P</given-names></name><name><surname>Yun</surname><given-names>HJ</given-names></name><name><surname>Lim</surname><given-names>SC</given-names></name><name><surname>Ahn</surname><given-names>SG</given-names></name><name><surname>Yoon</surname><given-names>HE</given-names></name><name><surname>Kang</surname><given-names>KW</given-names></name><name><surname>Hong</surname><given-names>R</given-names></name><name><surname>Choi</surname><given-names>HS</given-names></name></person-group><article-title>Proyl isomerase Pin1 facilitates ubiquitin-mediated degradation of cyclin-dependent kinase 10 to induce tamoxifen resistance in breast cancer cells</article-title><source>Oncogene</source><year>2012</year><volume>31</volume><fpage>3845</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1038/onc.2011.548</pub-id><?supplied-pmid 22158035?><pub-id pub-id-type="pmid">22158035</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>M</given-names></name><name><surname>Stukenberg</surname><given-names>PT</given-names></name><name><surname>Kirschner</surname><given-names>MW</given-names></name><name><surname>Lu</surname><given-names>KP</given-names></name></person-group><article-title>The essential mitotic peptidyl-prolyl isomerase Pin1 binds and regulates mitosis-specific phosphoproteins</article-title><source>Genes Dev</source><year>1998</year><volume>12</volume><fpage>706</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1101/gad.12.5.706</pub-id><?supplied-pmid 9499405?><pub-id pub-id-type="pmid">9499405</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Obchoei</surname><given-names>S</given-names></name><name><surname>Sawanyawisuth</surname><given-names>K</given-names></name><name><surname>Wongkham</surname><given-names>C</given-names></name><name><surname>Kasinrerk</surname><given-names>W</given-names></name><name><surname>Yao</surname><given-names>Q</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Wongkham</surname><given-names>S</given-names></name></person-group><article-title>Secreted cyclophilin A mediates G1/S phase transition of cholangiocarcinoma cells via CD147/ERK1/2 pathway</article-title><source>Tumour Biol</source><year>2015</year><volume>36</volume><fpage>849</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1007/s13277-014-2691-5</pub-id><?supplied-pmid 25296734?><pub-id pub-id-type="pmid">25296734</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wulf</surname><given-names>GM</given-names></name><name><surname>Ryo</surname><given-names>A</given-names></name><name><surname>Wulf</surname><given-names>GG</given-names></name><name><surname>Lee</surname><given-names>SW</given-names></name><name><surname>Niu</surname><given-names>T</given-names></name><name><surname>Petkova</surname><given-names>V</given-names></name><name><surname>Lu</surname><given-names>KP</given-names></name></person-group><article-title>Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun towards cyclin D1</article-title><source>EMBO J</source><year>2001</year><volume>20</volume><fpage>3459</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1093/emboj/20.13.3459</pub-id><?supplied-pmid 11432833?><pub-id pub-id-type="pmid">11432833</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>MR</given-names></name><name><surname>Choi</surname><given-names>HK</given-names></name><name><surname>Cho</surname><given-names>KB</given-names></name><name><surname>Kim</surname><given-names>HS</given-names></name><name><surname>Kang</surname><given-names>KW</given-names></name></person-group><article-title>Involvement of Pin1 induction in epithelial-mesenchymal transition of tamoxifen-resistant breast cancer cells</article-title><source>Cancer Sci</source><year>2009</year><volume>100</volume><fpage>1834</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1111/j.1349-7006.2009.01260.x</pub-id><?supplied-pmid 19681904?><pub-id pub-id-type="pmid">19681904</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Yuan</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Xu</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><etal/></person-group><article-title>RNA-interference-mediated downregulation of Pin1 suppresses tumorigenicity of malignant melanoma A375 cells</article-title><source>Neoplasma</source><year>2013</year><volume>60</volume><fpage>92</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.4149/neo_2013_013</pub-id><?supplied-pmid 23067222?><pub-id pub-id-type="pmid">23067222</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Obermayr</surname><given-names>E</given-names></name><name><surname>Castillo-Tong</surname><given-names>DC</given-names></name><name><surname>Pils</surname><given-names>D</given-names></name><name><surname>Speiser</surname><given-names>P</given-names></name><name><surname>Braicu</surname><given-names>I</given-names></name><name><surname>Van Gorp</surname><given-names>T</given-names></name><name><surname>Mahner</surname><given-names>S</given-names></name><name><surname>Sehouli</surname><given-names>J</given-names></name><name><surname>Vergote</surname><given-names>I</given-names></name><name><surname>Zeillinger</surname><given-names>R</given-names></name></person-group><article-title>Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance -- a study of the OVCAD consortium</article-title><source>Gynecol Oncol</source><year>2013</year><volume>128</volume><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/j.ygyno.2012.09.021</pub-id><?supplied-pmid 23017820?><pub-id pub-id-type="pmid">23017820</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>SS</given-names></name></person-group><article-title>Current implications of cyclophilins in human cancers</article-title><source>J Exp Clin Cancer Res</source><year>2010</year><volume>29</volume><fpage>97</fpage><pub-id pub-id-type="doi">10.1186/1756-9966-29-97</pub-id><?supplied-pmid 20637127?><pub-id pub-id-type="pmid">20637127</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanekura</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name></person-group><article-title>CD147/basigin promotes progression of malignant melanoma and other cancers</article-title><source>J Dermatol Sci</source><year>2010</year><volume>57</volume><fpage>149</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1016/j.jdermsci.2009.12.008</pub-id><?supplied-pmid 20060267?><pub-id pub-id-type="pmid">20060267</pub-id></element-citation></ref><ref id="CR91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chou</surname><given-names>CH</given-names></name><name><surname>Chang</surname><given-names>NW</given-names></name><name><surname>Shrestha</surname><given-names>S</given-names></name><name><surname>Hsu</surname><given-names>SD</given-names></name><name><surname>Lin</surname><given-names>YL</given-names></name><name><surname>Lee</surname><given-names>WH</given-names></name><name><surname>Yang</surname><given-names>CD</given-names></name><name><surname>Hong</surname><given-names>HC</given-names></name><name><surname>Wei</surname><given-names>TY</given-names></name><name><surname>Tu</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>miRTarBase 2016: updates to the experimentally validated miRNA-target interactions database</article-title><source>Nucleic Acids Res</source><year>2016</year><volume>2016</volume><issue>44</issue><fpage>D239</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1093/nar/gkv1258</pub-id></element-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hurley</surname><given-names>DG</given-names></name><name><surname>Budden</surname><given-names>DM</given-names></name><name><surname>Crampin</surname><given-names>EJ</given-names></name></person-group><article-title>Virtual Reference Environments: a simple way to make research reproducible</article-title><source>Brief Bioinform</source><year>2015</year><volume>16</volume><issue>5</issue><fpage>901</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1093/bib/bbu043</pub-id><?supplied-pmid 25433467?><pub-id pub-id-type="pmid">25433467</pub-id></element-citation></ref><ref id="CR93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hackenberg</surname><given-names>M</given-names></name><name><surname>Rodriguez-Ezpeleta</surname><given-names>N</given-names></name><name><surname>Aransay</surname><given-names>AM</given-names></name></person-group><article-title>miRanalyzer: an update on the detection and analysis of microRNAs in high-throughput sequencing experiments</article-title><source>Nucleic Acids Res</source><year>2011</year><volume>39</volume><fpage>W132</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1093/nar/gkr247</pub-id><?supplied-pmid 21515631?><pub-id pub-id-type="pmid">21515631</pub-id></element-citation></ref><ref id="CR94"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griffiths-Jones</surname><given-names>S</given-names></name></person-group><article-title>miRBase: microRNA sequences and annotation</article-title><source>Curr Protoc Bioinformatics</source><year>2010</year><volume>Chapter 12</volume><fpage>Unit 12 19 11&#x02013;10</fpage></element-citation></ref><ref id="CR95"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griffiths-Jones</surname><given-names>S</given-names></name></person-group><article-title>miRBase: the microRNA sequence database</article-title><source>Methods Mol Biol</source><year>2006</year><volume>342</volume><fpage>129</fpage><lpage>38</lpage><?supplied-pmid 16957372?><pub-id pub-id-type="pmid">16957372</pub-id></element-citation></ref><ref id="CR96"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griffiths-Jones</surname><given-names>S</given-names></name><name><surname>Grocock</surname><given-names>RJ</given-names></name><name><surname>van Dongen</surname><given-names>S</given-names></name><name><surname>Bateman</surname><given-names>A</given-names></name><name><surname>Enright</surname><given-names>AJ</given-names></name></person-group><article-title>miRBase: microRNA sequences, targets and gene nomenclature</article-title><source>Nucleic Acids Res</source><year>2006</year><volume>34</volume><fpage>D140</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1093/nar/gkj112</pub-id><?supplied-pmid 16381832?><pub-id pub-id-type="pmid">16381832</pub-id></element-citation></ref><ref id="CR97"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griffiths-Jones</surname><given-names>S</given-names></name><name><surname>Saini</surname><given-names>HK</given-names></name><name><surname>van Dongen</surname><given-names>S</given-names></name><name><surname>Enright</surname><given-names>AJ</given-names></name></person-group><article-title>miRBase: tools for microRNA genomics</article-title><source>Nucleic Acids Res</source><year>2008</year><volume>36</volume><fpage>D154</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1093/nar/gkm952</pub-id><?supplied-pmid 17991681?><pub-id pub-id-type="pmid">17991681</pub-id></element-citation></ref><ref id="CR98"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kozomara</surname><given-names>A</given-names></name><name><surname>Griffiths-Jones</surname><given-names>S</given-names></name></person-group><article-title>miRBase: annotating high confidence microRNAs using deep sequencing data</article-title><source>Nucleic Acids Res</source><year>2014</year><volume>42</volume><fpage>D68</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1093/nar/gkt1181</pub-id><?supplied-pmid 24275495?><pub-id pub-id-type="pmid">24275495</pub-id></element-citation></ref><ref id="CR99"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kozomara</surname><given-names>A</given-names></name><name><surname>Griffiths-Jones</surname><given-names>S</given-names></name></person-group><article-title>miRBase: integrating microRNA annotation and deep-sequencing data</article-title><source>Nucleic Acids Res</source><year>2011</year><volume>39</volume><fpage>D152</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1093/nar/gkq1027</pub-id><?supplied-pmid 21037258?><pub-id pub-id-type="pmid">21037258</pub-id></element-citation></ref><ref id="CR100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Der Walt</surname><given-names>S</given-names></name><name><surname>Colbert</surname><given-names>SC</given-names></name><name><surname>Varoquaux</surname><given-names>G</given-names></name></person-group><article-title>The NumPy array: a structure for efficient numerical computation</article-title><source>Computing in Science &#x00026; Engineering</source><year>2011</year><volume>13</volume><fpage>22</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1109/MCSE.2011.37</pub-id></element-citation></ref><ref id="CR101"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hunter</surname><given-names>JD</given-names></name></person-group><article-title>Matplotlib: A 2D graphics environment</article-title><source>Computing in science and engineering</source><year>2007</year><volume>9</volume><fpage>90</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1109/MCSE.2007.55</pub-id></element-citation></ref><ref id="CR102"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yates</surname><given-names>A</given-names></name><name><surname>Akanni</surname><given-names>W</given-names></name><name><surname>Amode</surname><given-names>MR</given-names></name><name><surname>Barrell</surname><given-names>D</given-names></name><name><surname>Billis</surname><given-names>K</given-names></name><name><surname>Carvalho-Silva</surname><given-names>D</given-names></name><name><surname>Cummins</surname><given-names>C</given-names></name><name><surname>Clapham</surname><given-names>P</given-names></name><name><surname>Fitzgerald</surname><given-names>S</given-names></name><name><surname>Gil</surname><given-names>L</given-names></name><etal/></person-group><article-title>Ensembl 2016</article-title><source>Nucleic Acids Res</source><year>2016</year><volume>44</volume><fpage>D710</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1093/nar/gkv1157</pub-id><?supplied-pmid 26687719?><pub-id pub-id-type="pmid">26687719</pub-id></element-citation></ref><ref id="CR103"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashburner</surname><given-names>M</given-names></name><name><surname>Ball</surname><given-names>CA</given-names></name><name><surname>Blake</surname><given-names>JA</given-names></name><name><surname>Botstein</surname><given-names>D</given-names></name><name><surname>Butler</surname><given-names>H</given-names></name><name><surname>Cherry</surname><given-names>JM</given-names></name><name><surname>Davis</surname><given-names>AP</given-names></name><name><surname>Dolinski</surname><given-names>K</given-names></name><name><surname>Dwight</surname><given-names>SS</given-names></name><name><surname>Eppig</surname><given-names>JT</given-names></name><etal/></person-group><article-title>Gene ontology: tool for the unification of biology. The Gene Ontology Consortium</article-title><source>Nat Genet</source><year>2000</year><volume>25</volume><fpage>25</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1038/75556</pub-id><?supplied-pmid 10802651?><pub-id pub-id-type="pmid">10802651</pub-id></element-citation></ref><ref id="CR104"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gene Ontology</surname><given-names>C</given-names></name></person-group><article-title>Gene Ontology Consortium: going forward</article-title><source>Nucleic Acids Res</source><year>2015</year><volume>43</volume><fpage>D1049</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1093/nar/gku1179</pub-id><pub-id pub-id-type="pmid">25428369</pub-id></element-citation></ref><ref id="CR105"><label>105.</label><mixed-citation publication-type="other">ImageJ. [<ext-link ext-link-type="uri" xlink:href="http://imagej.nih.gov/ij/">http://imagej.nih.gov/ij/</ext-link>]</mixed-citation></ref><ref id="CR106"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guzman</surname><given-names>C</given-names></name><name><surname>Bagga</surname><given-names>M</given-names></name><name><surname>Kaur</surname><given-names>A</given-names></name><name><surname>Westermarck</surname><given-names>J</given-names></name><name><surname>Abankwa</surname><given-names>D</given-names></name></person-group><article-title>ColonyArea: an ImageJ plugin to automatically quantify colony formation in clonogenic assays</article-title><source>PLoS One</source><year>2014</year><volume>9</volume><pub-id pub-id-type="doi">10.1371/journal.pone.0092444</pub-id><?supplied-pmid 24647355?><pub-id pub-id-type="pmid">24647355</pub-id></element-citation></ref><ref id="CR107"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smalley</surname><given-names>KS</given-names></name><name><surname>Lioni</surname><given-names>M</given-names></name><name><surname>Noma</surname><given-names>K</given-names></name><name><surname>Haass</surname><given-names>NK</given-names></name><name><surname>Herlyn</surname><given-names>M</given-names></name></person-group><article-title>In vitro three-dimensional tumor microenvironment models for anticancer drug discovery</article-title><source>Expert Opin Drug Discov</source><year>2008</year><volume>3</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1517/17460441.3.1.1</pub-id><?supplied-pmid 23480136?><pub-id pub-id-type="pmid">23480136</pub-id></element-citation></ref></ref-list></back></article>